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aa     Amino acid  
AAP    Amino acid permease  
AP    Alkaline Phosphatase  
ARG    Arginase  
BCIP    5-bromo-4-chloro-3-indoyl phosphate  
bp    Base pair 
CL    Cutaneous leishmaniasis 
CAT    cationic amino acid transporter 
Cter     C-terminal 
DNA    Deoxyribonucleic acid  
DSLR    Digital single-lens reflex  
EDTA    Ethylenediaminetetraacetic acid  
FT    Flow Through 
FT-BE    Flow Through Buffer Elution  
I    Induced  
IMAC    Immobilized Metal Affinity Chromatography  
IPTG    Isopropyl 𝛽-D-1-thiogalactopyranoside  
g    gravity of acceleration (~9,8 m/s2) 
g    gram 
h    hour 
hs    hours 
kb    kilobase 
kDa    kilodalton 
LB    Luria Broth  
LPG    Lipophosphoglycan  
M    Molar 
mg    Milligram 
min    Minutes  
ML    Mucocutaneous leishmaniasis 
mL    Milliliter  
mM    MilliMolar  
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NBT    nitroblue tetrazolium  
Ni-NTA   Nickel-nitrilotriacetic acid  
NO    Nitric oxide 
Nter    N-terminal  
O.D.    Optical density 
ORF    Open Reading Frame  
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SLA    Soluble Leishmania amazonensis  
S.O.B    Super Optimal Broth 
S.O.C    Super Optimal Broth with Catabolic repressor  
TAE    Tris-acetate-EDTA 
TBS    Tris-Buffered Saline 
TBST    Tris-Buffered Saline with Tween 20 
T7RNAP   T7RNA polymerase  
U    unit 
UI    uninduced 
µL    microliter 
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Leishmania is an intracellular protozoa causing the tropical disease leishmaniasis.   The 
disease is spread by female sandflies from the Phlebotomus and the Lutzomyia genera, and 
can cause diverse manifestations ranging from asymptomatic disease to lethal visceral 
leishmaniasis. The amino acid permease (AAP) transporter is conserved in the different 
Leishmania species, and is important for Leishmania survival and virulence. This makes the 
investigation on this protein important for development of new drug and vaccines.   
 The aim of this study was to successfully express and purify the LdAAP3 
(Leishmania donovani amino acid permease 3) transporter protein in E. coli and use this 
recombinant antigen to produce polyclonal antibodies in rabbit.   
 The LdAAP3 gene was cloned into a pET TOPO vector, for expression of 
recombinant protein in E. coli, and purified by affinity chromatography as His-tags were 
attached to the N-terminal (Nter) end of the target protein. The purified recombinant protein 
was quantified and injected in rabbits to raise polyclonal antibodies. Sera obtained from the 
injected rabbits were tested for their binding affinity to recombinant LdAAP3 protein or 
lysated Leishmania amazonensis by using Western blots and ELISA. 
The results from the expression were analyzed on different SDS-PAGE and Western 
blots, and revealed a successful expression of the LdAAP3 protein. Comparing the binding of 
antibodies from pre-immunized and immunized sera to LdAAP3 recombinant protein 
revealed a successful production of anti-LdAAP3 antibodies. ELISA experiments confirm 
that anti-LdAAP3 antibodies have binding affinity to epitopes of Leishmania amazonensis. 
Throughout the experiments a binding pattern was obtained by the observation of repeated 
protein bands often found at sizes around 56 kDa, 45 kDa, 38 kDa, 32 kDa, 26 kDa and 12 
kDa on SDS-PAGE and Western blots incubated with sera from infected subjects.  
In conclusion, the successful production of the LdAAP3 recombinant protein, lead to 
the production of polyclonal anti-LdAAP3 antibodies, which could be used for future 
localization of the AAP3 protein in Leishmania cells by imaging techniques such as confocal 
or electron microscopy. The LdAAP3 recombinant proteins also enabled detection of 
antibodies from infected subjects by binding to the epitopes on the recombinant protein. This 
gave a binding pattern that was characteristic for infected subjects. To be able to use this 
method for further diagnostics, experiments will have to be done comparing the binding 
specificity and avidity, and testing the similarities of similar genus like Crithidia and 
Leptomonas, which also produce AAP transporters.  
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ABSTRAKT 
Leishmania er en intracellulær protozo som fører til sykdommen leishmaniasis. Sykdommen 
spres med sandfluer av typen Phlebotomus og Lutzomyia. Den kan føre til ulike 
manifestasjoner fra asymptomatisk til dødelig visceral sykdom. Aminosyrepermeasene 
(AAP) er konservert i de ulike Leishmania-stammene, og er viktig for Leishmania sin 
overlevelse og virulens. Derfor har dette proteinet potensialle for utvikling av nye medisiner 
og vaksiner. 
Målet til denne studien var å uttryke og rense LdAAP3 (Leishmania donovani amino 
acid permease 3) transporter proteinet i E.coli, og bruke dette rekombinante proteinet til å 
produsere polyklonale antistoffer i kaniner.  
 LdAAP3 genet ble klonet i pET TOPO vektoren for ekspresjon av recombinant 
protein i E.coli, og renset ved hjelp av affinitets kromatografi siden proteinet inneholdt 
polyhistidine-tags. Det rensede rekombinante proteinet ble kvantifisert og kaniner ble 
immuniset med proteinet for å lage polyklonale antistoffer. Ved hjelp av Western blot og 
ELISA ble sera fra de inokulerte kaninene undersøkt for sin binding til det rekombinante 
LdAAP3 proteinet eller lysert Leishmania amazonensis. 
Resultatene fra ekspresjonen ble analysert ved SDS-PAGE og Western blot. LdAAP3 
proteinet ble uttrykt og renset. ELISA og Western blot analyser viste at antistoffer hadde blitt 
produsert når man sammenlignet serum fra før og etter immunisering i kaninene. ELISA 
eksperimenter bekreftet at anti-LdAAP3 antistoffer har bindingsaffinitet til epitoper på 
Leishmania amazonensis. Når Western blot ble inkubert med sera fra personer med 
leishmaniasis fant man proteinbånd ved rundt 56 kDa, 45 kDa, 38 kDa, 26 kDa og 12 kDa. 
For å konkludere, det rekombinante proteinet LdAAP3 ble produsert og ble brukt til å 
produsere polyklonale LdAAP3 antistoffer i kaniner. Antistoffer kan potensielt brukes til 
lokalisering av AAP3-proteinet i Leishmania parasitten. LdAAP3 proteinet ble også brukt til 
detektering av antistoffer hos personer med leishmaniainfeksjonen. For at metoden skal 
kunne brukes i diagnostikk vil eksperimenter måtte bli utført for å undersøke spesifisitet, 
sensitivitet og vurdere kryssreaktivitet til andre mikrober som Crithidia og Leptomonas, som 






















































































































































1.1 The obligatory intracellular protozoa, Leishmania 
1.1.1 Epidemiology  
Leishmaniasis is a tropical disease caused by protozoan parasites of the genus Leishmania, 
and it spreads by the bite of specific sandflies. It occurs in diverse areas, ranging from rain 
forests to desserts and cities, and can be found on every continent aside from the Antarctic 
and Australia. Evaluating the disease burden of leishmaniasis can be challenging due to lack 
of reliable data on incidence, duration, severity, and due to its clinical and epidemiological 
diversity (1). Each year up to 20.000-40.000 people die because of leishmaniasis. Over 12 
million people in the world are believed to be infected, and about 350 million people are at 
risk of infection (2). Leishmaniasis exists in three main clinical manifestations; visceral, 
mucocutaneous and cutaneous. There are an estimated 0.2-0.4 million visceral leishmaniasis 
(VL) cases, with more than 90% of these occurring in India, Bangladesh, Sudan, Ethiopia and 
Brazil (Figure 1). There are an estimated 0.7-1.2 million cutaneous leishmaniasis (CL) cases 
occurring each year. Afghanistan, Algeria, Brazil, Costa Rica, Ethiopia, Iran, North Sudan, 
Peru and Syria are the ten countries with the highest estimated case counts of CL (3). 
Southern European countries are also affected, and popular destinations such as Greece, Italy, 
Spain, Portugal, Cyprus, France, Turkey and Bulgaria are a few of the destinations countries 
with reported Leishmania incidences (Figure 1 and 2) (4). Children and elderly with reduced 
immune response and people using drugs suppressing the immune system are more 
susceptible to getting infected. The increase in travelling and the increase in migration from 
high endemic areas may increase the incidence in European countries (5). Leishmaniasis 
remains a disease of developing countries, and lack of investment and funding for research, 
in addition to its complicated biology makes it challenging to develop vaccines and 


































1.1.2 Pathology  
Manifestation of leishmaniasis varies from asymptomatic to critical illness. The three main 
forms are cutaneous leishmaniasis (CL), mucocutaneous leishmaniasis (ML) and visceral 
leishmaniasis (VL). The incubation time and severity of the disease will vary from different 
species of Leishmania, the health status of the infected subject, genetic variation and immune 
system of the infected host. CL normally occurs in areas of the body exposed to the sandflies, 
such as the neck, limbs and face. It generally starts off as a papule, and progress to a nodule 
and can become a dry or wet ulcer (Figure 3). Self-healing can occur without treatment. ML 
occurs in mucosal tissue, often in the nasal cartilage leading to nasal collapse (Figure 4). VL 
affects the inner organs especially the spleen and liver. Symptoms include fever, anorexia, 
weakness, hepatosplenomegaly, and is lethal if not treated (Figure 5) (1, 4, 8). Because 
Leishmania infect and proliferate in immune cells, co-infections tend to occur, especially in 
subjects with HIV (9, 10).  
 
 
Figure 3: CL on a leg. Figure taken from (11). 
Figure 4: ML in the mucosa of the nose. Figure taken from (11).  
Figure 5: VL of a 20 month old girl showing hepatosplenomegaly. 
Figure taken from (4). 
 
 
1.1.3 Diagnosis  
Various laboratory techniques can be used to diagnose leishmaniasis, and the specific species 
can be detected by isoenzyme analysis(12). Asymptomatic leishmaniasis is not well defined, 
but can be confirmed by a serological tests or polymerase chain reaction (PCR) test (13). 
Microscopic examination of Leishmania from tissue aspirates or biopsies from bone marrow, 
spleen, skin, lymph nodes and even in the blood can be used for diagnosis of the disease(14). 
Diagnosing VL can be particularly challenging because of the similarity of its clinical 
features compared to other diseases such as malaria, typhoid and tuberculosis, which are 




examination of relevant tissue, detection of parasite DNA in tissue using PCR or 
immunodiagnosis by detection of parasite antigen. Direct agglutination tests (DAT) are used 
by Médecins Sans Frontières (MSF) for diagnosis of VL, although agglutination is not 
observed before the next day (15, 16).  
 
1.1.4 Treatment  
Treatment of leishmaniasis infection will depend on the species of the infecting parasite, the 
innate host-immune response, geographical location, and the different types of diseases. 
Although the same species, regional difference can lead to different responsiveness to a 
medication. Dosing regiments will also vary regionally. The treatment options may vary from 
local therapy, encompassing topical and intralesional injections, to systemic therapy, 
including the most commonly used pentavalent antimonials, amphotericine B, and 
miltefosine (8, 17). With some exceptions, the treatment are expensive, have long duration of 
use and can generate many side effects (17). Liposomal amphotericin B is first line treatment 
for VL in Europe and the United States and shows relatively low toxicity. It is also the 
chosen treatment for Leishmania/HIV co-infected patients (18). The anti-cancer drug 
miltefosine, is the first effective oral drug for VL, but is also teratogenic (16). It has been 
used for over a decade, however the efficacy of miltefosine has declined, indicating that the 
parasite has developed resistance mechanisms (17). The main problem of treatment is the 
access and cost for both the medications and hospitalization. Poor people living in endemic 
areas are most affected, and is one of the reasons why finding a treatment with short 
treatment duration and easy administration is desired (8, 19).  
Using liposomal amphotericin B with either miltefosine or paramomycine, or 
paramomycine combined with miltefosine has proved to give an enhanced effect. 
Combination therapy gives increased treatment efficacy, reduced treatment time and cost, 
shows less toxicity, is better tolerated, and may prevent drug resistance (16, 17, 20). The 
different Leishmania species show different sensitivity to a drug, which results in different 
drug efficacy. Resistance to the different drugs against leishmaniasis seem to occur, which 







1.1.5. The Leishmania organism  
Leishmania is an obligatory intracellular protozoa of the Kinetoplastida order and the 
Trypanosomatidae family (2, 17). As of today, there is still no universal agreement on how to 
classify the different species of Leishmania (22). About 53 Leishmania species has been 
described, whereas 20 of those species are known to be pathogenic for humans (16, 22). L. 
donovani and L. infantum (also called L.chagasi) are the species known to cause VL. CL can 
be caused by numerous different species, which can vary from different geographical regions. 
ML can be caused by L. braziliensis, L. panamensis, and L. major (17). It is important to note 
that the disease outcome of a specific species can vary in different patients. L. donovani 
infections could result in an aggressive VL infection but could also lead to an asymptomatic 
infection (13). It is normal to divide the different Leishmania species into Old World or New 
World (Figure 6). It is a poorly defined division, based on the sandflie species and 
geographical origin.  
 
Figure 6: Classification of Leishmania species, The blue boxes indicate Old World species and the red boxes 
indicate New World species. Figure taken from Akhoundi et al. (22).  
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The unicellular Leishmania parasite differentiates between two main life cycle stages; the 
flagellated extracellular promastigote stage, which is motile and present in the sandfly vector, 
and the intracellular amastigote stage, which are nonflagellated and present within 
mammalian host cells and adapting to the hydrolytic environment of the lysosome (8, 23). 
The promastigotes reside in basic pH (about 7) with a mean temperature of 26℃, while the 
amastigotes reside in an environment with acidic pH of about 4.5-5.5 and temperatures 
between 33-37℃. As soon as amastigotes reaches an environment in neutral pH it will start 
differentiating to promastigotes (24). Asexual growth is typical for Leishmania parasites, 
although sexual recombination also seems to occur. Sexual recombination does not happen in 
vitro (25). The Leishmania parasite also contains kinetoplast, which are DNA-containing 
regions sitting in a large mitochondrion (26). Kinetoplastids contain glycosomes, which are 
peroxisome-like organelles (27).  
 
Figure 7: Contents of promastigotes and amastigotes Leishmania. Figure from PLOS Pathogens (28). 
 
1.1.6 Sandflies  
Sandflies are the known vector of Leishmania, with an estimation of about 30 species of 
phlebotomine sandflies that are able to transmit infection to humans (16). Over 800 sandfly 
species have been described, however, less than 10% have been confirmed to be vectors of 
Leishmania (29). The sandflies can be classified as Old and New World sandflies based on a 
phenetic approach, classifying the sandflies by their similarity (22). Specific sandflies 
transmit only a certain species of the parasite, Phlebotomus sandflies of the Old World and 
Promastigote Amastigote
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Lutzomyia of the New World species of Leishmania, and will infect the host with different 
presentations and progress (8, 26). The sandfly has to take a new blood meal for it to spread 
the infection, limiting the spread to female sandflies, who need blood for their reproduction 
(30). Some sandflies only have one blood meal during their entire life span. The infectiveness 
of the vectors may vary depending on time of blood meal excretion and the amount of 
lipophosphoglycan (LPG) on the parasites membrane enabling the parasite to bind to the mid-
gut of the vector (31).  
The complexity of the infection is further enhanced due to different variables in the 
host. Stress, host-immune system, general health status, age, sex, differences in the genome, 
may play an important role when fighting off the infection. Geographical and 
epidemiological differences will also play a role. People with low-grade housing, located 
near the habitat of infected vectors have increased risk of infection (13). Many species serve 
as reservoirs, such as humans, dogs, rodents, bats and lions. (32).  
 
1.1.7 The Leishmania life cycle  
The life cycle of the Leishmania parasite (Figure 8) starts with a bite of a female sandfly from 
an infected host. The parasite is transmitted to the sandfly from the blood of the infected host 
and will differentiate from the amastigotes to the non-infective procyclic promastigote stage 
due to changes in pH and temperature (33). The promastigotes differentiate from proliferating 
procyclic promastigotes to motile nectomonad promastigotes which are normally located in 
the anterior part of the midgut, before the parasites develop into leptomonad, haptomonad 
and finally the infective and non-dividing metacyclic promastigotes (34). A new blood meal 
must take place to spread the infection, and when this happens the sandfly will regurgitate 
metacylcic promastigotes into the host. Once the parasite is in the host cells of the innate 
immune system, they will phagocytize the metacylcic promastigotes through receptor-
mediated binding. Inside the phagolysosome the parasite will differentiate into the 
amastigotes form and start proliferating until the cell membrane is disrupted and amastigotes 






















Figure 8: The life cycle of Leishmania parasites. An infected female sandfly bites the host and transmits the 
parasite into the blood stream, where it enters the host cells of the innate immune system and differentiates into 
amastigotes. There it may proliferate until it disrupts the host cell membrane and can invade other cells. Figure 
taken from Kaye et al. (33).  
 
1.2 The Immune response and mechanisms behind arginase and L-arginine availability  
1.2.1 Immune response   
Leishmania parasites are found primary in the macrophages where they are engulfed and 
proliferate intracellularly (2). Macrophages have many defense mechanisms, among them is 
the oxidative burst induced by phagocytosis, vesicular acidification and induction of 
inducible nitric oxide synthase (iNOS) (27). To clear out the Leishmania infection we are 
dependent on the macrophages ability to produce nitric oxide (NO) by producing iNOS and 
other oxidative intermediates (2, 8).  
Macrophages are activated by cytokines, like interferon-gamma (IFN-𝛾) and 
interleukin-12 (IL-12), (Figure 9) (27). Interleukin-1 (IL-1), tumor necrosis factor-alfa (TNF-
𝛼), interferon-alfa (IFN-𝛼) and interferon-beta (IFN-𝛽) are cytokines also know to activate 
macrophages and induce upregulation of iNOS. Production of iNOS will catalyze L-arginine 
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to generate NO, which is toxic for the Leishmania parasites. Dendritic cells producing IL-12 
promotes protective immunity by stimulating Th1 cells and NK cells. The alternative 
macrophage activation leads to parasite survival. Cytokines produced by Th2, Treg and other 
macrophages produce cytokines, such as IL-4, IL-13, IL-10, and TGF-𝛽 favors parasite 
survival by inhibiting parasiticidal activity of infected cells (2).  
The proliferation and survival of the parasite inside the host is dependent on the 
balance between the factors in the host and parasite that control the activation or deactivation 
of the macrophages defense mechanism (2, 27). When the internal pool of arginine is not 
sufficient to sustain NO production, the macrophages will increase the expression of the 
arginine transporter CAT2B(35).  
Neutrophils are phagocytes able to uptake Leishmania in the early stages of infection. 
It has been proposed that they might function as “Trojan horse´s” for the parasite. Leishmania 
may induce apoptosis of the neutrophils rather than necrosis, thereby entering the 
macrophages without inducing reactive oxygen species (2).  
The disease pathology of the different species of Leishmania is variable. It is 
therefore very challenging and nearly impossible to generalize the infection mechanism to all 
hosts and strains (2).  
 
1.2.2 The importance of arginase and L-arginine  
Crithida, Leptomonas and Blastocrithidia are other genus aside from Leishmania that seem to 
express arginase (Figure 6)  (36). Arginase also called L-arginine amidinohydrolase is a 
trimeric metalloenzyme that generates L-ornithine and urea by catalyzing the hydrolysis of 
the amino acid L-arginine. L-arginine is important in several metabolic and physiological 
pathways and is a precursor for protein synthesis, NO, urea, ornithine, citruline, proline, 
glutamate, agmatine creatinine and polyamines (27). Leishmania parasites depend on external 
supply of L-arginine since it is an essential amino acid for Leishmania (37, 38).   
 Polyamine synthesis is essential for the cell replication and viability of the 
Leishmania parasite, and is dependent on the production of ornithine, which again can be 
generated from L-arginine by arginase (39, 40). Arginase can be found in the glycosome of 
both the promastigotes and the amastigotes, indicating that the arginine needs to be 
transported from the outside of the macrophages, through the parasitophorous vacuolum, 
through the Leishmania and finally through the glycosome in order to be used as a substrate 
for arginase (27, 41).  
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 In mammalian cells there are two arginase genes that code for arginase-I and 
arginase-II which differ in their relativities and distribution. Arginase-I is mostly found in the 
cytosol and expressed in the hepatocytes. Arginase-II is expressed in macrophages, intestines, 
mammary glands, kidneys and brain, and are localized in the mitochondria (40, 42). The 
Leishmania and human produced arginase seem to be quite similar. The main important 
differences are two non-conserved amino acids rendering a different channel like structure 
and a cleft containing a different charge (43). Because the arginase produced in the parasite 
and the host are so similar, screening for specific inhibitors to only target parasite arginase 
has not been successful (41). Being able to exploit those differences to inhibit only the 
Leishmania arginase would be a good target for a future chemotherapy (27).  
 It has been shown that in L. major, L. amazonensis and L. mexicana arginase 
knockout parasites lack polyamines. This confirms the importance of arginase for production 
of polyamines and the survival of Leishmania (Figure 9). An increase in NO production also 
occurred with L. mexicana arginase knockout parasites, which indicates the importance of L-
arginine availability. This was not the case for L. major, which further underlines the 
differences among Leishmania species (27).  
 
 
Figure 9: How Th1 and Th2 immune response can regulate iNOS and arginase. Th1 response activates 
inflammatory reactions and may lead to macrophage activation and antibody opsonization that will further 
enable the fight against the parasite. Th2 response will enable the humoral response and often exhibit anti-
inflammatory reactions, but will not be effective against the Leishmania parasite since it generally is located 
inside macrophages(42). L-arginine is a substrate for both arginase and iNOS, the Leishmania parasite and the 
macrophage will therefore compete for the L-arginine for their survival (27). Blue arrows represent stimulatory 
routes, while red dots represent inhibitory routes. Figure taken from da Silva et al. (2014).   
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1.2.3 The L-arginine transporter  
In mammalian cells L-arginine is transported through cationic amino acid transporters called 
CATs. In total there are six CAT family members called CAT1, CAT2A, CAT2B, CAT3, 
CAT4 and CAT14, which carries L-arginine, L-lysine and L-ornithine. When responding to 
cytokines produced during Th1 and Th2 immune responses the CAT2B is responsible for the 
transportation of arginine into the macrophages. When this transporter is blocked iNOS and 
arginase levels are undetected underlining the importance of this transporter but also 
suggesting that the concentrations of arginine inside the cell will have an impact on the amino 
acid metabolism by iNOS and arginase. An increase in CAT2B expression and a decrease of 
iNOS expression is detected during a Th2 response in macrophages infected with 
Leishmania. This will lead to increased levels of arginine available for parasite to utilize for 
growth and replication, which also underlines the importance of an arginine transporter to the 
parasite (27).  
 The AAP3 (amino acid permease3) contains 480 amino acids and 11 trans-
membrane domains, and is a highly specific arginine transporter (37, 44). Permeases are 
responsible for amino acid uptake driven by membrane potential created by H+-pumps. To 
date, AAP genes has been cloned from plants, mammals and protists, and has been 
characterized for yeast and protozoa (37).  L. donovani contains eight AAP (amino acid 
permease) genes and is able to sense decrease in arginine levels and respond by increasing 
arginine uptake (37).  
Similar to the L. major and L. infantum, the L. donovani genome has two identical 
copies of LdAAP3. These L. donovani copies show a 93% similarity to the L. amazonensis 
copies with 98% similarity of the ORF (open reading frame). The two identical LdAAP3 
(Leishmania donovani AAP3) copies are arranged in tandem on chromosome 31. The 
5´UTRs (untranslated region) of the LdAAP3 copies are identical while the 3´UTR copies are 
different, which give rise to two different transcripts (35, 37).  
Leishmania parasites exhibit polycistronic transcription and therefore lack the control 
mechanism of gene expression at the transcription level. However, Leishmania can control 
gene expression at the mRNA maturation level and also by changing mRNA half-lives in 
different conditions (35). This is a possible explanation for the presence of two copies of the 
AAP3 gene. Each copy could be regulated differently according to the current environment 
of the parasite. The mRNA transcripts of the two different copies seem to have different 
stability, and will therefore differ in how much and how long it can be translated. The 
stability of the mRNA can be regulated by the external and intracellular amino acid 
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concentration. In this way, it is postulated that Leishmania can regulate the arginine transport 
as needed (35).  
Though activity of the AAP is registered at a broad pH range, it is more active at pH 5 
than pH 7. The transporter may therefore be more active when inside the macrophages (37). 
Localization of the LdAAP3 using green fluorescence protein has localized the LdAAP3 on 
the surface membranes of promastigotes (37).  
 The arginase reaction has been localized in the glycosome, although some authors 
suggest that the glycosomal location is not essential for arginine function in promastigotes 
(40). Da Silva et al (2012), on the other hand, confirm how the lack of arginase and incorrect 
localization may reduce infection and parasite proliferation. They also showed that the 
arginase remains in the glycosome during macrophage infection (41). The results from their 
study done for L. amazonensis indicate the importance of the proper compartmentalization of 
the arginase in the glycosome for enzyme activity and parasite infectivity.   
According to Shaked et al (2006) it is likely that the glycosome functions as an 
intracellular pool for arginine, which means it has to be transported through the glycosomal 
membrane, which again implies the need of another arginine transporter (37). The transporter 
that leads the arginine to the glycosome still remains unknown (Figure 10).    
The importance of the glycosomal compartmentalization of the arginase for parasite 
infectivity, and the differences between the parasite and host transporter makes further 
investigations into the arginase transporters relevant. New treatments against leishmaniasis 
may reside by the inhibition of arginine trafficking to the parasite and by blocking the 








Figure 10: “L-arginine traffic through macrophages infected with Leishmania. Arginine is taken up by 
macrophage (Mø) through CAT-2B membrane transporter. In the cytoplasm of the Mø the amino acid is 
metabolized by Mø’s arginase (ARG II) or iNOS, or is taken up by parasitophorous vacuolum (PV) through an 
unknown mechanism. In order to reach Leishmania’s arginase(ARG), L-arginine must be taken up by the 
parasite through the AAP3 transporter and then must reach the glycosome (g) by unknown mechanisms”. This 
text and figure is taken from da Silva et al. (27).  
 
1.3 The expression of recombinant proteins in E. coli  
To obtain a desired quality of a recombinant protein choosing an appropriate method and 
system is critical and there are numerous expression systems to choose from. Knowing the 
characteristics and intended application of the recombinant protein may increase the success 
of the expression. This may lead to a better selection of expression system and enable the 
production of sufficient proteins (45).  
 Protein misfolding, poor expression, the lack of posttranslational modifications or 
inappropriate modifications can occur when the wrong expression host is chosen. Aspects 
one must consider when selecting the appropriate expression system include posttranslational 
modifications desired on the protein, destination of the protein, the proteins intended use, and 
it’s mass and number of disulfide bonds. However, there are still may circumstances that 
needs to be optimized which makes expression approaches time consuming and challenging 
(45).  
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Expressing prokaryotic and eukaryotic recombinant proteins in Escherichia coli (E. 
coli) is a commonly used technique, and allows the production of a wide variety of proteins 
from a variety of organisms (46, 47). It offers rapid and inexpensive expression of 
recombinant proteins. 
Expression in an E. coli strain that can co-express tRNAs for rare codons can be 
preferable if the protein contains a high number of rare E. coli codons. When the recombinant 
protein contains increased amount of disulfide bonds, it may be preferable to choose an E. 
coli strain with a more oxidizing cytoplasmic environment to stimulate proper folding. When 
dealing with toxic proteins choosing an E. coli strain containing vectors that allow a tight 
regulation of the expression system is favorable. Membrane-bound protein expression seem 
to be favored in mutant strains like C41(DE3), C43(DE3) (47, 48) and Lemo21 (DE3) (49). 
 
1.3.1 Inclusion body formation  
Recombinant proteins expressed in E. coli can be directed to the periplasm, to the cytoplasm 
or be secreted from the bacteria cell. High expression levels can often result in aggregation of 
the recombinant protein forming inclusion bodies (45). Expression under high temperatures, 
high inducer concentration and strong promoter systems may result in higher translation rates 
of the recombinant protein. This may overwork the quality control system of the bacteria host 
resulting in completely or partially misfolded aggregates of the protein, forming inclusion 
bodies. Factors like reduced environment in the bacterial cytosol, lack of post-translational 
machinery and chaperones may increase the chance of protein aggregation and inclusion 
body formation (50). Although inclusion bodies require comprehensive processing to isolate, 
solubilize, refold and purify the protein to produce bioactive proteins, it may also offer some 
advantages. Inclusion bodies are often resistant to proteolysis and are easy to concentrate 
using centrifugation and thereby minimalizing contamination of other proteins when 
purifying (45, 50).  
 
1.3.2 Protein Solubility  
Several steps can be improved to maximize the formation of properly folded soluble proteins. 
Lowering the expression temperature to 15-30 ℃ can slow the rate of transcription, 
translation and refolding which allows the host to properly fold the proteins. It can also 
decrease the heat shock protease activity, which may lessen the protein degradation (45).  
 Co-expressing the recombinant protein with molecular chaperones can promote 
protein solubility, but has to be tested individually for each protein due to the chaperones 
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protein specificity. Fusing the recombinant protein to a soluble fusion tag to the N-terminus 
or C-terminus part of the protein may also increase the solubility (45).  
 
1.3.3 Codon usage  
Most amino acids can be encoded by more than one codon. Each organism has its own bias 
when it comes to using the 61 available amino acid codons (51). The genes of parasites use 
codons that may be rarely used in E. coli (52). It is important to consider the bias for codon 
usage in E. coli, which is mirrored by the abundance of the tRNA pools. Expressing a protein 
using several of these rare codons can lead to misincorporation of amino acids, premature 
termination of translation and frameshifts in translation, which may lead to the failure of 
expressing the recombinant protein with the desired property (45).  
 
1.3.4 Toxic proteins  
Many of the genes expressed in E. coli interfere with the survival of the E. coli. These 
expressed proteins can be toxic for the E. coli and cause maintenance defects during growth 
or even cell death (53). Toxic proteins can therefore be challenging to express, but can 
usually be overcome. 
One way to circumvent the toxicity is by tight regulation of the transcription and 
translation of the toxic genes. Tightly regulated inducible expression systems have been 
developed for E. coli and Yeast cell (Pichia Pastoris). This will allow a more controlled 
regulation of the recombinant protein by using inducible promoters, transcription terminators, 
modifications of the coding sequence, and by optimizing plasmid copy number. If the 
recombinant proteins toxicity is host cell specific, it is wise to choose a more compatible 
expression host (45, 53).  
Manipulating the copy numbers of the vectors may also increase the level of 
expression of toxic proteins. To keep the E. coli stable while maintaining the highly toxic 
gene, a low-copy number of the vector is favorable. To be able to express high quantities of 
the recombinant protein, an increase in vectors prior to induction is favorable. Therefore, 
using a system with a low-copy number of the vector, that can be increased before induction 
would be optimal. This copy number can be controlled by expression using thermo sensitive 





1.3.5 Expressing toxic membrane proteins  
E. coli BL21(DE3) is a commonly used host for overexpression of proteins. This strain has 
the gene of the target protein located on a plasmid, which is under the control of a T7 
promoter. The T7 promoter is activated by the T7RNAP (T7 RNA polymerase) with its gene 
located on the chromosome of the bacteria. The expression of the T7RNAP is induced by the 
non-titratable IPTG (Isopropyl 𝛽-D-1-thiogalactopyranoside) which induces the lacUV5 
promoter that is located in front of the T7RNAP gene (49).  
Lemo21(DE3) is a BL21(DE3) strain supplied with another plasmid containing a gene 
for an inhibitor of the T7RNAP, called T7 lysozyme (Figure 11). This gene is under the 
control of the well-titratable rhamnose promoter. Using this strain allows us to modulate the 
amount recombinant protein expressed by inhibiting the T7RNAP as needed using different 
concentrations of rhamnose, which will induce the production of T7 lysozyme inhibitor. The 
amount of rhamonse that is optimal for production of a certain protein needs to be 
individually tested, as the proteins are different (49). 
Membrane protein expression occurs naturally in low abundance. Because of this, 
isolating sufficient amounts of recombinant membrane proteins needs to be obtained from 
overexpressing systems, which often tends to be toxic for the host. The Lemo21(DE3) strain 
is suggested to be a well-suited host for the production of recombinant membrane proteins 
(49).  
Although using the Lemo21(DE3) strain for production of toxic recombinant proteins, 
leaky protein expression can still affect the system and cause toxicity. A small amount of the 
T7RNAP coming from a single copy of the gene is enough to produce high transcription 
levels of the target protein (53).  Leaky genes of the lacUV5 promoter may lead to the 
production of T7RNAP before induction, and may cause cell death to the host if the target 




















Figure 11: Lemo21(DE3) strain and the expression of a target membrane protein. The gene for the target 
protein is located on the pET plasmid. The pLemo plasmid contains the T7lysozyme gene. When T7lyzosyme is 
expressed it can bind and inhibit the T7RNAP which may lead to less expression of the target protein (49).  
 
1.3.6 Tagging recombinant proteins  
When expressing recombinant proteins, tags, also called fusion proteins, can be used to 
improve solubility, for protein detection and quantification, and to enable affinity 
purification. During the cloning step the fusion proteins can be added to the N-terminal (Nter) 
or C-terminal (Cter ) end of the protein of interest. Placing the tag on the Nter can be an 
advantage because of the translation initiation site and because of the endoproteases that cut 
at or close to the Cter of their recognition sites (56).  
 Affinity tags are important during protein purification, and allow target protein to 
bind on an affinity matrix containing immobilized metal ions. The His-tag contains six or 
more consecutive histidine residues and is one of the most used purification tags. The 
histidine residues have affinity for Ni2+ (nickel) or Co2+ (cobalt) metal ions that normally are 
immobilized on beads or resins for purification. To immobilize the metal ions on the beads or 
the resin linkages such as NI-NTA (Ni(II)-nitrilotriacetic acid) or Co2+-carboxymethyl-
aspartate can be used. This system is called immobilized metal affinity chromatography 




 IMAC is relatively cheap and has high binding capacities at about 5-40mg of His-
tagged protein per mLof media. The nickel metal ion can often be stripped from the resin 
when EDTA buffers are used. Cobalt is more specific for His-tags and has minimal metal 
leakage (56). Because the His-tag can bind to the IMAC resins without any special protein 
conformation, purification during denaturing conditions is possible. The binding to the IMAC 
resins may also be enhanced because of the increased exposure of the His-tags in denatured 
condition (56).  
 The histidine imidazole ring on the His-tag bind to the immobilized metal, and can be 
eluted using buffers containing imidazole (100-300 mM) or low pH (4.5 – 6). The 
concentrations of imidazole needed may vary from different proteins. Low concentrations of 
imidazole (5-20 mM) should be added to the loading and washing buffers to get rid of 
endogenous protein that exhibit weak binding to the IMAC media (56).  
 His-tags are small in size and may have little impact on the structure of the folded 
protein. Though the tag can be removed by introducing a protease cleavage site, keeping the 
tag allows protein detection by using His-tag-specific antibodies (56). 
 
1.4 Aims of the study   
This work was part of a larger project for the characterization of the arginine transporter 
AAP3 from Leishmania, where the ultimate goal is development of new drugs and vaccines. 
Availability of specific antibodies is an important tool for studying function and effects of 
components of organisms. The main aim of this study was therefore to raise antibodies 
against the arginine transporter (LdAAP3) from Leishmania donovani. 
 
The specific aims of this study: 
• To optimize the production of recombinant LdAAP3 in E.coli 
• To establish a method for purification of the recombinant protein 
• To produce and purify recombinant protein in a quantity that enabled immunization of 
rabbits 
• Immunization of rabbits with the recombinant protein 
• Characterize binding patterns from sera of infected and non-infected individuals using 
the LdAAP3 recombinant protein  
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2. MATERIALS AND METHODS  
2.1 Strains and vectors  
2.1.1 Champion pET151 Directional TOPO Expression Kit 
This kit comes with reagents, One shot TOP10 chemically competent E. coli, BL21 Star 
(DE3) One Shot Chemically competent E.col, and pET 151/D-TOPO vector. To clone and 
express LdAAP3 ORF, Nter and Cter genes the pET Directional TOPO system was chosen. 
The system utilizes a highly efficient 5 min cloning strategy to directionally clone a blunt-end 
PCR product into a vector for high level, T7-regulated expression in E. coli (57).  
 
2.1.2. Strains 
Leishmania (Leishmania) amazonensis (MHOM/BR/1973/2269) 
L. (L.) donovani (MHOM/IN/80/DD8)   
 
Escherichia coli One Shot TOP10 Chemically Competent (ThermoFisher Scientific, USA) 
was used for efficient transformation of all plasmid DNA used in this work. 
E. coli BL21 Star(DE3) (ThermoFisher, USA) was used for expression and induction of Nter 
construct. 
E. coli Lemo21(DE3) (NewEngland BioLabs, USA) was used for expression and induction 
of Cter and ORF construct.  
 
2.1.3 Vectors  
The LdAAP3 gene was cloned into the pGEM-T easy vector (Promega, Madison, WI, USA). 
This construct was obtained from Professor Lucile M. Floeter-Winter and her group at the 
University of São Paulo (USP), Brazil(41).  
The pET151/D-TOPO (ThermoFisher, USA), vector allows expression of 
recombinant protein with Nter tag containing the V5 epitope and a 6xHis tag. It contains 








Figure 12: Flowchart demonstrating the workflow steps conducted during this thesis. The protocol number 
marked in white can be found in several parts of this thesis. It is meant to give an overview over the different 
combinations of steps done throughout the whole proses from cloning, transformation, expression and so on. 
The light blue boxes show the different attempts made. The dark blue boxes indicate steps chosen to move 
forward with, completing the expression and purification of LdAAP3 recombinant protein and the testing of the 




























































































































































2.2 DNA Replication and Purification  
 
2.2.1 Polymerase Chain Reaction (PCR) 
The PCR mix reaction (final volume of 50 µL) included: 1X Pfx50 PCR buffer mix, 0.3 mM 
of dNTP mix, 0.3 µM of each of forward and reverse primer, 5 units of Pfx50 DNA 
polymerase (Invitrogen) and 100 pg of DNA. PCR conditions were 1 cycle at 95ºC for 5 min, 
followed by 35 cycles of denaturation at 95ºC for 30 sec, annealing at 52ºC-60ºC (the 
temperature given for each individual reaction) for 1 min and extension at 72ºC for 1min, 
followed by a final extension at 72ºC for 7 min on Veriti thermal cycler (Life technologies, 
USA)(58). 
 
2.2.2. Agarose gel preparation and gel electrophoresis 
1% agarose (SeaKem LE, ME, USA) was melted in TAE-buffer (40mM tris-acetate, 1mM 
EDTA, pH 8,0). When the mix was slightly cooled, 3𝜇L GelRed (Invitrogen, USA)  
(1:10,000) was added. The mix was poured onto a horizontal gel Electrophoresis system (Life 
Technologies, USA) and left to set for 1h. 10 𝜇L of PCR samples were mixed in 2 𝜇L loading 
buffer and loaded on the gel (6x8,5cm) and run at 80V for 1h using TAE as running buffer. 
Gels were visualized using UVIProChemi  (Uvitec, Cambridge, UK) set at 300nm (59, 60).  
 
2.2.3 Purification of PCR product  
QIAquick PCR Purification Kit (Qiagen, Germany) was used for purification of double 
stranded PCR products (100bp-10bp). The principle of this technique is that DNA from the 
PCR products adsorbs to the silica membrane when high salt concentrations are added, while 
the contaminants pass through the column. DNA is released from the silica in low salt 
concentrations. Adsorption to the silica is improved at pH ≤7,5. This column provides high 
yields of pure nucleic acid, giving good substrates for further ligation and transformation 
processes (61).  
5 volumes of buffer PB with 100% ethanol was added to 1 volume of PCR product 
and loaded onto a QIAquick column with a 2mL collection tube. This was centrifuged for 30 
sec at 17900 x g, at room temperature (RT). 0.75mL buffer PE was added to the column for 
washing, then centrifuged for 30 sec, at 17900 x g, at RT. The centrifugation was repeated for 
1 min to remove residual wash buffer. The QIAquick column was placed into a clean 1.5mL 
microcentrifugation tube, before 50𝜇L buffer EB (10mM Tris-Cl, pH 8,5) was added for 
elution. The column was then centrifuged for 1 min (61). 
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2.2.4 Cloning  
When using QIAprep
 
Miniprep (Qiagen, Germany) for lysis of E coli, the bacterial cells were 
lysed with alkaline, enabling the adsorption of DNA onto silica. This silica membrane has a 
selective adsorption to plasmid DNA in high salt buffer solutions, and elutes the DNA in low 
salt buffer solutions. Elution efficiency is maximized when pH is between 7.0 and 8.5 (62).  
The recovered PCR products from the pGEM-T easy vector were cloned directly into 
pET151/D-TOPO (Invitrogen, USA) according to the manufacturers instructions. Ligated 
products were then transformed to E. coli TOP10 chemically competent cells (Invitrogen). 
Positive colonies were isolated from LB-agar plates containing ampicillin (100𝜇g/mL) and 
then by MiniPrep kit (Qiagen, Germany), according to the manufacturers instruction.  
 
2.2.5 Transformation into competent cells 
Transformation protocol into E. coli competent cells was based on the protocol described by 
Chung and Miler (1988), with some modifications. E. coli TOP10 competent cells 
(Invitrogen, USA) were used to propagate the DNA. Cells were thawed on ice and mixed 
with 3 µL of pET TOPO construction. Tubes were swirled gently and incubated on ice for 30 
min. After incubation, cells were heat-shocked (Eppendorf Thermomixer Comfort, Germany) 
at 42°C for 30 sec and then immediately transferred on ice for 5 min. Then, 800 µL of the 
SOC medium was added to the cells and incubated at 37°C for 1h with shaking (311DS 
Labnet) at 250 rpm. For positive selection, 100 µL of transformation mixtures were plated on 
LB agar plates containing ampicillin (100 µg/mL) and incubated at 37°C (Termaks, Norway). 
 
2.2.6 Plasmid purification  
Plasmid purification was performed according to the QIAprep instruction kit. E. coli was 
grown overnight in 1 mL LB medium, pelleted by centrifugation, and resuspended in 250𝜇L 
buffer P1, containing RNase A. 250 𝜇L buffer P2, and 350 𝜇L buffer N3 (Qiagen, Germany) 
was added before centrifugation for 10 min at 17900 x g. The supernatant from the 
centrifugation was loaded onto the QIAprep spin column and further centrifuged for 30 sec. 
The flow through was discarded. 0.5mL buffer PB was added to the column for washing, and 
centrifuged for 30 sec. The flow through was discarded before applying 0.75mL buffer PE 
and centrifuged for another 30 sec. The flow through was discarded before a final 
centrifugation for 1 min, to remove residual wash buffer. The QIAprep column was then 
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placed in a clean 1,5mL microcentrifuge tube, 50 𝜇L Buffer EB (10mM Tris-Cl, pH8,5) was 
added for elution, before the last centrifugation for 1 min (62).  
 
2.2.7 Sequencing  
The constructs were confirmed if they were cloned in frame by BigDye v.3.1 Sequencing 
(ThermoFisher, UK), performed using the Applied Biosystem 3730XL Analyzer at “Seksjon	
for	laboratoriediagnostikk”	at	the	“Senter	for	medisinsk	genetikk	og	molekylærmedisin”	
(MGM),	Haukeland	University	Hospital,	Bergen. 
 Sequencing analysis were performed using Sequencing Scanner Software (Applied 
Biosystem by ThermoFischer) and GenBank of Leishmania by TriTryp Database 
(www.tritryp.org). 
 
2.3 Expression of LdAAP3 ORF, Nter and Cter recombinant protein 
Sequencing verified successful cloning regarding size of the inserts and correct reading 
frames. The plasmid containing the entire 1440 bp open reading frame (ORF) was called 
pET151-ORF, the plasmid containing 311 bp from the 5’ end of the ORF was called pET151-
Nter, and the plasmid containing the last 453 bp of the ORF was called pET151-Cter. 
 Small scale expression was performed to determine the IPTG induction, incubation time and 
the solubility. After the standardization of the settings, big scale expression was performed.  
 
2.3.1 Expression and transformation of LdAAP3 Nter recombinant protein 
Expression of LdAAP3 Nter was performed using E. coli BL21 Star(DE3) competent cells 
(ThermoFisher, USA). 3 µL of the pET151-Nter plasmid was added to a vial (50𝜇L) 
containing E. coli BL21 Star(DE3) One Shot (ThermoFisher, USA). Contents were gently 
mixed, incubated on ice for 30 min, heated at 42℃ for 30 sec, then incubated on ice for 2 
min. 900 µL LB-media was added to the mix incubated for 1 h, at 37℃ with 200 rpm on 
shaker, Shaker Control System, (Dublin, Ireland). 100 µL was spread on an agar plate 
containing ampicillin (100 µg/mL). The agar plate was incubated at 37℃ for 18 hs.  
Colonies were recovered into 3 mL of LB with ampicillin (100 µg/mL), incubated 
overnight at 37ºC, with 250 rpm shaking.  
The overnight culture was diluted 1:50 in fresh LB with ampicillin (100 µg/mL) to 
OD600 0.6-0.8 (Eppendorf BioPhotometer, Germany) using 8,5 mm cuvette. 1 mL of 
uninduced culture was removed, centrifuged at 9300 x g, for 3 min at RT. The pellet was 
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frozen for later gel analysis. IPTG (1 mM) was added for induction of expression of 
recombinant protein. 1 mL aliquot was removed, centrifuged at 9300 x g, for 3 min at RT, 
and froze the pellet for gel analysis. Aliquots were removed every 1 h of incubation time to 
standardize the induction incubation time (1 to 6 hs).  
After the induction, the bacteria culture was centrifuged at 4500 x g, for 15 min, at 
4ºC, the pellet was eluted into lysis buffer (20 mM sodium phosphate pH 8, 500 mM NaCl, 5 
mM imidazole, 1 mM PMSF and 1 mg/ mL lysozyme) and sonicated on Misonic Sonicator 
3000, (Newton,USA), for 30 min (30 sec on, 90 sec off, 15W).  The lysate was clarified by 
centrifugation (20817 x g, 15 min, at 4ºC). Since LdAAP3 Nter was in inclusion bodies, the 
pellet of lysate was solubilized using solubilization buffer (20 mM sodium phosphate pH 8, 
500 mM NaCl, 8 M urea, 5 mM imidazole) and incubated at room temperature, stirring, 
overnight. The solubilized solution was centrifuged at 20817 x g, 30 min, at 4ºC and the 
supernatant was further used in Dynabeads His-Tag purification. 
 
2.3.2 Expression and transformation of LdAAP3 ORF and Cter recombinant proteins 
4 µLof the pET151-ORF or pET-Cter plasmid was added to an E. coli Lemo21(DE3) vial, 
mixed gently, incubated on ice for 30 min, heated at 42℃ for 10 sec, then incubated on ice 
for 5 min. Added 250 µL S.O.C and incubated for 1 h, in 37℃ with 200 rpm on shaker. 
100µL was spread on agar plate containing ampicillin (100 µg/mL), chloramphenicol 
(30 µg/mL) and L-rhamnose (500 µM). The agar plate was incubated at 37℃ for 18 hs.  
Colonies were recovered into 3 mL of LB with ampicillin (100 µg/mL) and 
chloramphenicol (30 µg/mL), incubated overnight at 37ºC, with 250 rpm on shaker.  
The overnight culture was diluted 1:50 into fresh LB with ampicillin (100 µg/mL), 
chloramphenicol (30 µg/mL) and L-rhamnose in different concentrations (0 to 2000 µM), 
using 200rpm, at 30-37℃, for about 3h, until OD reached OD600 0.3-0.6. 1 mL of uninduced 
culture (UI) was removed, centrifuged at 9300 x g, for 3 min at RT, and froze the pellet for 
gel analysis.  
When standardizing incubation time after induction with IPTG, 1 mL of uninduced 
culture containing 2000 𝜇M L-rhamnose was saved for gel analysis. IPTG (400 µM) was then 
added to all aliquots with different amount of L-rhamnose, for induction of expression of 
recombinant protein. 1 mL aliquot was removed, centrifuged at 9300 x g, for 3 min at RT, 
and froze the pellet for gel analysis. Aliquots were removed from incubation after 4hs, 18hs 
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and 24hs, to standardize the induction incubation time (4 to 24hs) and the L-rhamnose 
concentration. 
When not standardizing incubation time after induction, aliquots from the first 
incubation for 3 hs were added IPTG (400 µM), incubated on shaker for 4h at 200rpm, at 20-
30℃. The culture was again diluted 1:50 into fresh LB with ampicillin (100 µg/mL), 
chloramphenicol (30 µg/mL) and L-rhamnose in different concentrations (0 to 2000 µM), 
using 200rpm, at 27-30℃, and incubated for 16-18hs. 1 mL aliquot was removed, centrifuged 
at 9300 x g, for 3 min at RT, and froze the pellet for gel analysis. The rest of the culture was 
centrifuged at 3220 x g, at 4℃, for 15min. 
The pellet was eluted into lysis buffer (4 different lysis buffers described in Appendix 
E were tested), incubated for 15-60 min at RT, 9rpm, and sonicated using Misonic Sonicator 
(Newton, USA), for 30 min (30 sec on, 90 sec off, 15W).  The lysate was clarified by 
centrifugation (20817 x g, 15 min, at 4ºC). 1 mL aliquot was removed, centrifuged at 9300 x 
g, for 3 min at RT, and froze the pellet for gel analysis. The rest of the supernatant was saved 
for further purification steps.  
All aliquots, pellets and supernatants, saved for gel analysis were stored at -20℃, and 
thawed prior to gel analysis. Pellets were resuspended in 150𝜇l - 500𝜇l Milli-Q water before 
applying to gel. 
 
2.3.3  Lysation using Ni-NTA Superflow Cartridge 
When using Ni-NTA Superflow Cartridge column for purification a different lysis protocol 
was followed and was done according to the manual from Qiagen, Ni-NTA Superflow 
Cartridge Handbook (63).  
5mL of NPI-10 buffer was added to each gram of wet pellet, lysozyme (0.1mg/mL) 
and Triton (0,1%) was added, then incubated on Echo Therm, at 30℃ using a Stuart rotator 
(Stone, United Kingdom), for 15 min. Sonicated in two sets with the same settings; 10 sec on, 
10 sec off, W12, 6 rounds (2 min), on ice to minimize the heat.  
To pellet cellular debris and spin down unbroken cells and heavy nuclei, the sonicated 
solution was centrifuged at 4℃, 10 007 x g for 30 min on Sorvall RC 5C Plus (Delaware, 
USA), using a Sorvall SS-34 rotor. Pellets were saved for later gel analysis while proceeding 




2.3.4 Ultra Centrifugation steps 
In the following section, different centrifugation attempts are listed along with the protocol 
number. Lysated solutions prior to these centrifugations were taken right after the sonication.  
 
• Protocol #5: Lysate was centrifuged using 10000 x g, in 4℃, for 15 min and continued 
with supernatant with 1% SDS, then incubated on Stuart, Rotator (Stone, United 
Kingdom), for 1h, 9rpm, and 40 degrees incline. The lysate supernatant was then 
ultracentrifuged at 92600 x g, 4℃, for 1h. 4 mL solubilization buffer (20mM Sodium 
Phosphate, 300mM NaCl) and 1mM PMSF was added to the pellets, and set on the 
rotator for 1h, RT at 30 degrees incline. Solubilized pellet was then ultracentrifuged at 
92600 x g, in 4℃, for 30 min.  
• Protocol #8: Lysated solution was centrifuged at 20000 x g, in 4℃, for 15 min. 
Supernatant was further used for ultracentrifugation at 500 000 x g, at 4℃, for 1h.  
• Protocol #9: The lysate was at 20000 x g, in 4℃, for 15 min. Supernatant was then 
ultracentrifuged at 165 000 x g, in 4℃, for 1h. Pellet was resuspended into 20 mL lysis 
buffer and 1mM PMSF, and then passed through a syringe (21G) five times. The 
resuspended pellet was then ultracentrifuged with the same settings for 1h. The pellet was 
then resuspended into 15 mL lysis buffer, 1mM PMSF and CHAPS (1%), and incubated 
on the roller with 9rpm, 400 incline, for 1h, then set on ultracentrifugation with the same 
settings for another hour.  
	
2.4 Purification 
2.4.1 Immobilized Metal Affinity Chromatography (IMAC): 
The mechanism of adsorption of a protein when using IMAC is based on an interaction 
between an immobilized metal ion (Cu2+, Ni2+, Zn2+, Co2+, Fe3+) and an electron donor group 
located on the surface of the protein to be purified. These electron-donor atoms like N, S, and 
O can be found in for example histidine, cysteine and tryptophan and form chelates when 
bound to a metal compound (64).  
 
2.4.2 Dynabeads His-Tag Isolation and Pulldown 
Dynabeads are magnetic beads used to purify small volumes of different target molecules. 
The beads are coupled with IMAC chemistry, and are bound to a metal chelator with affinity 
to histidine residues due to two out of six coordination sites on cobalt (Co2+) that are 
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unoccupied. When the His-tagged protein produced from E. coli occupy these two remaining 
coordination sites, a covalent bond is generated. Dynabeads are superparamagnetic and loose 
all their magnetic remanence once the magnetic field is removed. Beads at a size of 1𝜇m in 
diameter are suited for purification of proteins and nucleic acids (65).  
Because of the size, the beads have limited binding capacity and surface area. 
Increasing the volume of the Dynabeads may help overcome low binding capacities, but may 
as well lead to increased nonspecific adsorption and sample loss due to dilution of the sample 
with His-tag (66).  
During small scale production purification was done using Dynabeads His-Tag kit 
(Life Technologies, Oslo, Norway), according to manufacturer’s instructions (67). All 
fractions of purification steps were collected for gel analysis (flow through, washing 1, 
washing 2, washing 3 and eluted). Buffers were also changed from the manufacturers 
instructions to contain increasing imidazole concentrations, which can be seen in Appendix 
E. 
 
2.4.3 IMAC columns  
Both the HisTrap HP and Ni-NTA superflow cartidge use the IMAC system with Ni2+ as the 
immobilized metal ion and have great affinity for histidine residues (68). Ni2+ shows high 
metal ion stability, and is less susceptible to transfer its metal ion to the protein (69).  
 
2.4.4 His-Trap HP column 
His-Trap columns enabled purification of bigger amounts of sample at once. The purification 
protocol was done according to the HisTrapTM HP manual from GE Healthcare Life Sciences 
(70). In addition to this manual we used washing buffers with increasing imidazole 
concentration.  
The column was washed with 10 mL Milli-Q water, then equilibrated with 10 mL 
1HisTrap HP-binding buffer. Lysated protein solution was passed through the column 1-3 
times before 10 mL of washing buffer 1 was passed through the column, followed by 10 mL 
of washing buffer 2, and then 10 mL of washing buffer 3 and finally 10 mL of elution buffer. 
The solution that passed through the column was saved for subsequent gel analysis. 
Elution of the protein by pH differences was attempted by using the 2HisTrap HP-
buffers. When pH is lowered to 4.0 the imidazole on the histidine residue will be protonated, 
and will not be able to bind to the metal ion resulting in elution from the column (64, 71, 72). 
We started washing the column with 10 mL water, at a speed of 30 drops per min. Then 
	 39	
passed through 10 mL 2HisTrap HP-lysis buffer, before passing through the lysated 
recombinant protein solution three times to make sure the proteins were able to bind to the 
column. 10 mL 2HisTrap HP-washing buffer 1 was then passed through, followed by 10 mL 
2HisTrap HP-washing buffer2, and finally 10 mL 2HisTrap HP-elution buffer. The flow 
through was saved for gel analysis. 
 
2.4.5 Ni-NTA Superflow Cartridge column 
The purification was done according to the manual from Qiagen, Ni-NTA Superflow 
Cartridge Handbook (63).  
The Ni-NTA Superflow Cartridge column (Qiagen, Hilden, Germany) was 
equilibrated with 10 mL NPI-10 buffer counting 30 drops a min. Bacterial lysate containing 
the recombinant protein obtained from the 2.3.3 lysation using the Ni-NTA Superflow 
Cartridge was passed through the column with the same flow rate. 10 mL of NPI-20 buffer 
was then passed through the column, and then 10 mL of NPI-250 buffer, and finally 10 mL of 
Buffer E (elution buffer from denaturizing conditions) was added as a final step to see if this 
could elute proteins that might be left on the column. Samples from the flow through were 
saved for gel analysis. 
 
2.4.6 Filtration 
To concentrate and purify the purified solution further, the Amicon Ultra-15 centrifugal filter 
(Merck, Germany) was used, with a 3 molecular weight cut-off. The solution from 
purification step containing the LdAAP3 recombinant protein was added to the Amicon filter, 
centrifuged at 2330 x g, 23℃, for 30 min.  
 
2.4.7 SDS-PAGE 
SDS-PAGE (Sodium Dodecyl Sulfate - Polyacrylamid Gel Electrophoresis) is a technique 
used to separate molecules according to their molecular weight. Separation is generated as 
the proteins move through a sieving gel matrix in response to an electric field. Gel pore size 
is adjusted by the ratio between the acrylamide monomer and the cross-linker. The gel 
commonly consist of a stacking gel (4%) with larger pores on the top, and a resolving gel 
with an increasing gradient (until 12%) and smaller pores towards the bottom. The higher the 
percentage gives a higher polymer-to-water ratio, which gives smaller pore sizes (73). The 
protein is heated on 70℃ for 10 min, to denature the protein. Sample buffer added to the 
protein solution will keep the protein denatured, and the reducing agent will remove the 
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secondary and tertiary structure(74). SDS is a negatively charged detergent that will 
denaturize the protein, bind to it and give it a negative charge.  
Protein fractions were analyzed by SDS-PAGE, using 4-12% Nu-PAGE Bis-Tris gel 
(Invitrogen, USA). 5 µL sample buffer (Invitrogen, USA), 2 µL reducing agent (Invitrogen, 
USA), was added per 10-35 µL of sample The mixture was heated at 70℃, for 10 min, then 
put on ice for 2 min before applying 20-40 µL of the contents per well on the gel. 
4-10 µL of ladder SeeBlue Plus2 Pre-Stained Protein (Life Technologies, CA, USA) 
was used as a ladder. Precision Plus Protein TM Unstained Standards (BioRad, CA, USA) was 
used as a ladder when using ImageJ for quantification. 
Running settings were 80V for 30 min, then 150V for 1 h. The gels were stained with 
Coomassie Blue (0.1%) mixed with acetic acid (10%) and ethanol (30%), for 1-2 hs. Acetic 
acid(10%) and ethanol (30%) was used for destaining overnight.  
Alternatively, the gel was transferred to nitrocellulose membrane for Western blot 
analysis. 
 
2.5 Quantification of protein  
2.5.1 ImageJ 
After purifying the expressed LdAAP3 recombinant proteins they were further used for 
production of anti-LdAAP3 polyclonal antibodies by immunization of rabbits. Because 
BioGenes GmbH (Germany) wanted the protein in a concentration of 100-200𝜇g/500𝜇l, we 
had to quantify the target protein. For this we chose to use ImageJ (75). This allowed an 
estimate of the amount LdAAP3 recombinant proteins in a band per well on the SDS-PAGE, 
and was done by comparing the density/intensity of the bands. An image of the SDS-PAGE 
gel was taken with a DSLR camera and uploaded in ImageJ. Image was set on grey-scale at 
32-bit, with auto brightness/contrast. Rectangular lanes were drawn for each well using the 
Rectangular option on the toolbar. 
By pressing “command” and “3” a profile plot showed the relative density of the 
different bands in each rectangular lane. The peak of interest on the profile plot was defined 
using the Straight option on the toolbar and marked using the Wand tool (Figure 23)  
Each marked peak gave a value shown in the Results Window. These arbitrary 




2.5.2 Quantification calculations  
The equations below were used to calculate the amount of the LdAAP3 recombinant protein 
in the band of interest compared to the ladder band with known amount. Precision Plus 
Protein Standards, Unstained from BioRad (CA,USA) had a band at 50 kDa with a known 
amount of 750ng.  
 
 
• Calculating amount protein to ng: 
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• Calculating 𝝁g/𝝁l: 
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2.6 Raising anti-LdAAP3 polyclonal antibodies 
After the purification steps, the LdAAP3 protein solution was loaded on an SDS-PAGE. By 
comparing Western blots and SDS-PAGE with the same aliquots, two bands at the size of 32 
kD (N1) and 26 kDa (N2) were chosen for immunization. These bands were cut out from the 
gel and shipped to BioGenes GmbH in Germany for immunization in 4 different rabbits. Two 
rabbits were immunized with gel slices from bands at the size of about 30-32 kDa, called N1. 
Two other rabbits were immunized with gel slices from bands at the size of about 26 kDa, 
called N2. Pre-serum was obtained before the first immunization. The immunization was then 
boosted twice to further enhance the immune response, before the rabbit was bleed rendering 
the blood from which the sera containing anti-LdAAP3 polyclonal antibodies were obtained.  
 
2.7 Protein Blotting  
This procedure was used to confirm the LdAAP3 recombinant His-Tagged proteins produced 
from E. coli Lemo21 containing the pET TOPO151-ORF plasmid, and to detect antibodies 
produced against the LdAAP3 recombinant protein from sera of Leishmania spp. infected 
animals and humans.  
 
2.7.1 WesternBreeze Chromogenic Immunodetection System 
This system contains a secondary antibody conjugated with Alkaline Phosphatase (AP). The 
enzyme (AP) converts several substrates to a colored precipitate giving a colorimetric 
detection of the matching antibodies. AP catalyzes BCIP (bromochloroindyl phosphate) and 
NBT (nitro blue tetrazolium) to produce a stable purple precipitate, visualizing the protein on 
the Western blot (76).   
 
2.7.2 Blotting LdAAP3 recombinant protein on nitrocellulose membrane 
Foam pads, filter papers and Nitrocellulose membrane, Amersham Hybond ECL 0.2𝜇m (GE 
Healthcare), were soaked in transfer-buffers for 10 min. A sandwich of gel, nitrocellulose 
membrane, filter papers and foam pads were set in a chamber, X Cell II (Life Technologies, 
CA, USA), and filled with NuPAGE transfer buffer (CA, USA). Fridge-cold Milli-Q water 
was added to the two outer chambers of the device. The transfer was performed for 90 min at 
40V, and placed in a cold room at 4℃. The blotted nitrocellulose membrane paper was 
removed from the devise. The membrane was blocked with blocking buffer for 1h, at RT, on 
the Belly Dancer (Stovall, USA).  
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2.7.3 Detecting the His-Tagged LdAAP3 recombinant proteins  
After blocking the blotted nitrocellulose membrane for 1h, TBST (Tris-Buffered Saline with 
Tween 20) was added three times, and then placed on The Belly Dancer (Stovall, USA), at 
RT, for 5 min. TBST was discarded, and then AP conjugated HisG Epitope Tag primary 
antibody (mouse/IgG2a, Thermo Scientific, USA) was added at a dilution of 1:2000 and 
incubated on The Belly Dancer (Stovall, USA), for 2 hs at RT. 
The solution was discarded before TBST was added to the membrane, and incubated 
for 5 min. This was repeated three times before adding TBS once and alkaline phosphatase 
buffer twice, with 5 min incubations. The alkaline phosphatase buffer was then discarded, 15 
mL of Chromogen containing BCIP (bromochloroindyl phosphate) and NBT(nitro blue 
tetrazolium) was added, (Invitrogen, Carlsbad, CA, USA), until clear bands started showing. 
Washing with Milli-Q water was done for 10 min, before letting the membrane dry.  
 
2.7.4 Testing sera from Leishmania infected and non-infected individuals   
LdAAP3 recombinant protein blotted on nitrocellulose membrane from step 2.7.2 was cut 
into strips. The strips were washed 3-4 times in 4,5 mL CryoTube vials (Thermo Scientific, 
Denmark) with PBST (Phosphate Buffered Saline with Tween 20), with 5 min incubation and 
60rpm on Orbital Shaker (Biosan, Latvia). The PBST was discarded, blocking buffer and 
different amounts of sera from infected test subjects was added to each tube, and was 
incubated overnight, 2 hs or 1h.  
 The solution containing sera and blocking buffer was discarded. The membranes were 
washed 3-4 times with PBST. Another washing step with PBS was added in later attempts. 
The secondary antibody was added to blocking buffer in a 1:5000 ratio, and added to each 
tube with strips and incubated for 1h, while covered with aluminum foil. Then the strips were 
washed 3-4 times with PBST, then once with PBS in later attempts. Strips were scanned on 
the Odyssey scanner (Lincoln, NE, USA) set on a channel of 700nm.  
 
2.7.5 Dot-Blot 
Five strips of nitrocellulose membrane were cut to fit into 4,5 mL CryoTube vials (Thermo 
Scientific, Denmark). 3𝜇l of a 50:50 ratio mix of NPI-20 and NPI-250 flow through 
containing recombinant protein, in five different dilutions, was added to five strips of 
nitrocellulose paper. Two lines were marked on each strip for negative control. 3 𝜇l of 
MilliQ-water was added between these marked lines, and let dry for 15 min.  
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 The strips were blocked with TBS+5%BSA, incubated for 1h on the Belly Dancer 
(Stovall, USA), in RT. Thereafter, the strips were washed four times with TBST, on the Belly 
Dancer (Stovall, USA), at RT for 5 min between each wash, and then washed once with TBS. 
TBS was discarded. TBS+5%BSA and primary antibody, serum from rabbit injected with E. 
coli produced LdAAP3 recombinant protein, was added in different dilutions, then incubated 
for 1 at RT on the Belly Dancer (Stovall, USA).  
TBST was added three times for washing, and once with TBS. Secondary antibody 
conjugated with alkaline phosphatase (Thermo Scientific, USA) was added and incubated for 
1h, at RT, on the Belly Dancer (Stovall, USA), before washing three times with TBST and 
once with TBS.  
BCIP/NBT was added to the strips and incubated at RT, on the Belly Dancer  
(Stovall, USA), until bands showed. Finally the strips were washed with Milli-Q water for 10 
min and dried in RT.  
 
2.7.6 Testing anti-LdAAP3 polyclonal antibodies against E. coli produced LdAAP3 proteins 
These nitrocellulose membrane strips were produced following the Ni-NTA lysis and 
purification protocols. These membrane strips were blocked for 1h and cut into strips 
containing ladder, SeeBlue Plus2 Pre-Stained Protein, as a marker.  
The strips were washed by adding 20 mL TBST 3 times, and once with TBS, with 5 
min incubation, at RT, using the Belly Dancer (Stovall, USA). Each strip was placed into a 
CryoTube vial (Thermo Scientific, Denmark). Blocking buffer and sera from rabbit injected 
with the LdAAP3 recombinant protein was then added in different dilutions, and incubated 
for 2 hs on the Belly Dancer (Stovall, USA) at RT. After 2h the fluid was discarded, the strips 
were then washed four times with TBST, then washed 1 time with TBS. 2 mL secondary 
antibody conjugated with alkaline phosphatase (Thermo Scientific, USA) was added to the 
strips and incubated for 1h, on the Belly Dancer (Stovall, USA) at RT, then washed four 
times with TBST, and once with TBS. The strips were then washed two times with alkaline 
phosphatase buffer, with 5 min incubation, at RT, using the Belly Dancer  (Stovall, USA). 
The buffer was discarded, before BCIP/NBT was added. The strips were incubated in 
BCIP/NBT until clear bands started showing. Finally the strips were washed with Milli-Q 





2.7.7 Production of Soluble Leishmania antigen (SLA)  
Leishmania amazonensis (MHOM/BR/73/M2269) was kept in M199 supplemented with L-
glutamine, Hanks salts, 10% fetal bovine serum, 5 ppm hemin, 100 µM adenine, 50 U/mL 
penicillin, 50 µg/mL streptomycin, 40 mM HEPES and 12 mM sodium bicarbonate, at 26°C, 
until stationary phase. 2.5x108/mL of parasites were harvested and centrifuged at 800 x g, for 
10 min, at RT. The supernatant was removed and the pellet was washed with Dulbecco PBS 
(pH 7.4) and centrifuged again. This step was done three times. After resuspending the pellet 
in Dulbecco PBS, the parasites were lysated by repeated freeze and thaw; frozen in liquid 
nitrogen for 5 min and thawed in RT, respectively. This step was also done three times. The 
protein concentration was determined by the Direct Detect infrared spectrometer (Merck 
Millipore, Germany) using the direct detect assay-free green cards and the software NIST-
BSA standard.  
 
2.7.8 Testing SLA and recombinant LdAAP3 against anti-LdAAP3 antibody using ELISA 
Anti-LdAAP3 polyclonal antibodies produced in rabbits (Biogenes GmbH, Germany) were 
evaluated by ELISA. Flat-bottomed microtest plates (Sarstedt, USA) were coated with 10 
ug/mL of either the purified recombinant protein or a soluble Leishmania amazonensis 
antigen, overnight, at 4°C.  The antigens were diluted in 0.5 M carbonate buffer (pH 9.5). 
After the overnight incubation, the plates were washed with TBS with 0.1% Tween-20 and 
blocked with 100 µL of 5% BSA (bovine serum albumin) in TBS (tris-buffered saline) with 
0.1% Tween-20, for 1 h at RT. Thereafter, the blocking-buffer was removed and 100 µL pre-
immune or immune anti-AAP3 polyclonal antibodies were added at various dilutions (1:100-
1:1600 for pre-immune, and 1:100-1:52000 for immune), for 1 h on a Thermo Shaker 
(Biosan, Latvia) at 250 rpm at room-temperature. After washing with TBS with 0.1% Tween-
20, 100 µL of goat anti-rabbit IgG-Horseradish peroxidase (GE Healthcare, UK) was added 
at 1:2000 dilution in TBS with 0.1% Tween-20 and 0.1% BSA for 1h on a shaker (250 rpm) 
at RT. After washing, 100 µL of 1-step ultra 3,3´,5,5´-tetramethylbenzidine (Thermo 
Scientific, USA) substrate was added to each well. The reaction was stopped with 100 µL of 
2M sulfuric acid. The plates were read at 450 nm on a Synergi H1 Hybrid reader (BioTek 




3. RESULTS  
3.1 DNA replication and purification  
The gene encoding the AAP3 from L. donovani, cloned into the pGEM-T easy vector, was 
obtained from the research group of Professor Lucile Floeter-Winter, USP, Brazil.   
 
 
Figure 13: The ORF (open reading frame) of the LdAAP3 gene and the deduced amino acid sequence.Image 
obtained from MacVector software (MacVector Inc, NC, USA) 
 
Analysis of the deduced amino acid sequence indicated that the protein contained 11 
transmembrane spanning domains (Figure 15). It was therefore determined to perform the 
expression in E. coli using three different approaches; cloning of the N-terminal part (Nter), 
cloning of the C-terminal part (Cter) and cloning of the entire ORF, respectively.  
 
3.1.1 PCR and gel electrophoresis  
The forward primers were designed including four base sequences (CACC) underlined. The 
following primers were designed: 
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LdAAP3_F: 5´CACCATGAGCAAGCCTAACGAGC 3´ 
LdAAP3_R: 5´CTACACGAAGAAGCTGTAGTAGATCGTCG 3´  
LdAAP3_NT_R:  5´ CTAGACGACGGCATCGAGATGATACC 3´ 
LdAAP3_CT_F:  5´ CACCGACGATACGCAGGACTC 3´ 
 
The primer pairs (LdAAP3_F, LdAAP3_NT_R), were used for the Nter-, (LdAAP3_CT_F, 
LdAAP3_R) were used for Cter, and (LdAAP3_F, LdAAP3_R ) were used for ORF-
segments. 
The PCR products were run on a 1% agarose gel, stained with GelRed and 
photographed under UV-light. The results from the gel electrophoresis allow us to visualize 
the size of the PCR products. The picture (Figure 14) revealed bands corresponding to 
fragments of expected size, confirming a successful cloning.  
 
                  
Figure 14: Electrophoresis in 1% agarose gel stained with GelRed (Invitrogen), representing PCR 
amplification of LdAAP3 open reading frame (ORF), LdAAP3 Nter and LdAAP3 Cter. 1kb Invitrogen ladder. 
GelRed fluorescent stain starts emission once it is bound to the DNA. Because they are fluorescent they will 
absorb visible UV light and transmit the energy as visible light (77). 
 
 
Figure 15: Transmembrane helix prediction of the LdAAP3 amino acid sequence. Nter has 138aa giving a size 
at about 14,6 kDa and one transmembrane domain. Cter has 183aa giving a size of about 20.7 kDa and two 
transmembrane domains. The whole ORF has 514aa giving a size at about 56,2 kDa with 11 transmembrane 
domains. Figure is obtained from the Phyre2 web portal for protein modeling, prediction and analysis (78).  
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3.1.2 Cloning and transformation of the ORF, Nter and Cter plasmid into competent cells 
Purified DNA from the PCR products of the pGEM-T easy vector were cloned into the 
pET151/D-TOPO expression plasmid (Invitrogen, USA). This plasmid was transformed into 
E. coli One Shot TOP10 Chemically Competent (Invitrogen, USA) for general cloning of 
blunt-end PCR products. Single colonies were picked, inoculated for growth in LB medium 
with ampicillin, and processed for isolation of plasmid DNA. The resulting plasmids were 
designated pET151-ORF, pET151-Nter and pET151-Cter, respectively. 
The purified plasmids were then transformed into the E. coli BL21 Star(DE3) and E. coli 
Lemo21(DE3), which contain the proper genetic elements for expression of recombinant 
proteins.  
The plasmid pET151-Nter turned out not to be stable in E. coli BL21 Star(DE3). 
After some trials and errors it was determined to terminate the work with both pET151-Nter 
and pET151-Cter, and focus entirely on pET151-ORF.  
 
3.2 Expression of the LdAAP3 ORF recombinant protein 
3.2.1 Standardization of L-rhamnose concentration and incubation time after induction  
E. coli Lemo21 allows tunable expression by varying the amount of L-rhamnose added. To 
determine an optimal concentration and incubation time a pilot experiment was done with 
different incubation times and concentrations of L-rhamnose added.  
 
 
Figure 16: SDS-PAGE showing aliquots from standardization expression steps. Samples were incubated in 37 
℃, for 4, 18 and 24 hs containing concentrations of 0, 100, 500, 1000 and 2000 𝜇M of L-rhamnose. Uninduced 
aliquots were taken after 3h incubation with L-rhamnose and were not added IPTG. 400𝜇M IPTG was added to 











































The uninduced (UI) aliquots showed quite weak bands. Aliquot 1, 6 and 11 were all induced 
with 400𝜇M IPTG, but was not added L-rhamnose. Band 1 and 6 seems to be weaker than 
the according bands with different amounts of L-rhamnose but same incubation time. Bands 
from the 24-hs induction seem to be quite similar in band intensity. When comparing all the 
bands together, it seems the bands get stronger the longer the incubation time, which may 
seem logical because the E. coli has more time to produce more protein. The bands also get 
stronger with higher concentrations of L-rhamnose. Since there were no major differences in 
band intensity from the 18 to the 24h incubation we decided to continue with the 18h 
incubation. Lane number 8-10 seemed to have stronger bands, so we decided to continue with 
500 and 1000 𝜇M of L-rhamnose in our protocols.  
 
3.2.2 Combinations of temperature, incubation time and L-rhamnose concentration  
Less expression of the recombinant protein may lead to more production of protein of 
interest, because of less toxicity and stress for the E. coli. Attempts were done to find the best 
combination of temperature, incubation time and concentration of L-rhamnose that would 
give good conditions for ORF production, and enable us to produce the LdAAP3 
recombinant protein properly folded and unfragmented. 
 When analyzing the different gels obtained from several experiments it seems that 
expression using lower temperature (around 20℃) gives more protein production. Comparing 
gels when using 500 or 1000 𝜇M L-rhamnose, the difference does not seem to be of major 
importance for production and purification of the LdAAP3 recombinant protein, and show 













Table 1: Quick overview of the different combinations of temperature, incubation time and L-






OD600 was between 
0.3 and 0.6 
Second incubation: 
After 4h of induction 








Protocol #1: 30℃, 
3h, 250rpm  
30℃, 4 h, 250rpm 30℃, 16-18hs, 
250rpm 
Protocol #2: 30℃, 
3h, 250 rpm  






Protocol #2: 30℃, 
3h, 250 rpm  
27,4℃, 4 h, 200rpm  26℃, 16-18hs, 
200rpm  
Protocol #3: 
30℃, 2h, 250 rpm  
30℃, for 1h and 30 min, 
250rpm . Then 20℃ for 






2 h, 200rpm  
23℃, 4 h, 200rpm 23℃, 16-18hs, 
200rpm 
Protocol #12: 
37℃, 1h and 30min, 
200rpm 




Protocol # 4,5,6: 
37℃, 2 h, 200rpm  
23℃, 4 h, 200rpm 23℃, 16-18hs, 
200rpm 
 
3.2.3 Lysis and Centrifugation  
In order to purify the LdAAP3 recombinant protein expressed in E. coli Lemo21, lysation 
steps were necessary. Lysation could break up the cell wall and cell membrane of the E. coli 
and free the LdAAP3 recombinant protein from the E. coli. Changes during lysation were 
done to find the optimum amount of pellet, buffers and settings that allowed good lysation 
yielding good solutions for purification, which is shown in Table 2.  After lysis the solution 
containing lysated E. coli Lemo21 went through several centrifugation steps in attempts to 
direct more of the LdAAP3 recombinant protein to the pellet, some explained under 2.3.4 
Ultra Centrifugation steps. 
Lysis was verified by pipetting up and down, yielding a slimy consistence, with a 
visible line from the pipet tip to the solution due to destruction of the cell wall and liberation 
of DNA (79). Sonication showed to be successful by testing with a pipet to see that the 
fluidity had increased, due to cells and DNA being sheared.  
 When comparing the gels (all images not shown) it seems that centrifugation steps 
helps further separation of the LdAAP3 recombinant protein bands and unwanted bands that 
may come from intact cells, nuclei and other heavy organelles. Shorter sonication also 
seemed to benefit the purification.  
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Table 2: Overview of the different changes made during lysis. Pellets from the end of the 
expression step were used. Changes were done to amount pellets used, amount buffer added 
for each pellet, different incubation time, and different sonication and centrifugation settings. 
For small scale production one pellet was obtained from 10 mL of centrifuged overnight 
solution containing E. coli Lemo21 and the pET TOPO 151 plasmid containing the LdAAP3 
ORF sequence. For big scale production one pellet was obtained from 50 mL centrifuged 
overnight solution.  
 




Sonication  Centrifugation  
Small scale: Protocol #1 






30℃, 60rpm.  
20 min, 30sec 
on, 90 sec off, 
level 5, 15W. 
10 000xg, 4℃, 15 
min. Protein assumed 
in supernatant.  
Small scale: Protocol #2 













30 min, 30sec 
on, 90 sec off, 
level 5, 15W. 
#1. 10 000xg, 4℃, 15 
min. Protein assumed 
in supernatant.  
 
#2. 20817xg, 4℃, 30 
minutes.  Protein 
assumed in pellet.  
Small scale: Protocol #3 









15 min, 30sec 
on, 90 sec off, 
level 5, 15W. 
#1. 10 000xg, 4℃, 15 
min. Protein assumed 
in supernatant.  
 
#2. 20817xg, 4℃, 45 
min.  Protein assumed 
in pellet.  
 
#3 10 000xg, 20℃, 30 
min.  
Big scale: Protocol #4 










30 min, 30sec 
on, 90 sec off, 
level 4,5, 12W. 
#1. 10 000xg, 4℃, 15 
min. Protein assumed 
in supernatant. 
 
#2. 20817xg, 4℃, 45 
min.  Protein assumed 
in pellet. 
Big scale: Protocol #5 











20 min, 30sec 
on, 90 sec off, 
level 4,5, 12W. 
#1. 10 000xg, 4℃, 15 
min. Protein assumed 
in supernatant. 
 
#2. 92600xg x 2 
protein assumed in 
pellet.  
Big scale: Protocol #7 











20 min, 30sec 
on, 90 sec off, 
level 4,5, 12W. 
20817xg, 4℃, 15 min. 
Protein assumed in 
supernatant. 
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Big scale: Protocol #8 











20 min, 30sec 
on, 90 sec off, 
level 4,5, 12W. 
#1. 20 000xg, 4℃, 15 
min. Protein assumed 
in supernatant.  
 
#2. 500 000xg (ultra) 
Protein assumed in 
pellet. 
Big scale: Protocol #9 



















20 min, 30sec 
on, 90 sec off, 
level 4,5, 12W. 
#1. 20 000xg, 4℃, 15 
min. Protein assumed 
in supernatant.  
 
#2. 165000xg x2 
(ultra) 
Protein assumed in 
pellet then in 
supernatant after last 
centrifugation.  
Big scale: Protocol #9,2 











20 min, 30sec 
on, 90 sec off, 
level 4,5, 12W. 
20817xg, 4℃, 15 min. 
Protein assumed in 
supernatant. 
Big scale: Protocol #11 





















was so fluid. 
20817xg, 4℃, 15 min. 
Protein assumed in 
supernatant. 
Big scale: Protocol #12 











min, 30℃, 9 
rpm.  
2 rounds (2 
min in total per 
round) with 
10s on, 10s off, 
level 4,5.  
10007xg, 30 min, 4℃.  











3.2.4 Results from SDS-PAGE analysis  
During the expression and purification, aliquots of the samples containing E. coli Lemo21 


























Figure 17: SDS-PAGE showing that the LdAAP3 recombinant protein may be in both pellet and supernatant. 
This gel is from protocol #3 using 1000 𝜇M L-rhamnose, 20℃ overnight, 1 pellet from expression step 
resuspended in 10 mL lysis buffer, 15min sonication, centrifuged at 10 000 x g, 20817 x g and 10 000 x g, 
purification using 1Dynabeads buffers. Lysate supernatant and Lysate pellet are aliquots taken from the first 
centrifugation round. Lysate sup2 and lysate pellet2 are obtained from the lysate supernatant centrifuged for 
the second time.   
 
Table 3: Content of the aliquots from Figure 17. Each sample lane was added 5 𝜇L sample 
buffer, 2 𝜇L reducing agent, 3 𝜇L water and 10 𝜇L protein sample, and gave a total of 20 𝜇L 




Aliquots on the SDS-PAGE obtained from 
Ladder SeeBlue Plus2 Pre-Stained Protein (Life Technologies, CA, USA) 
UI: Un-Induced Undiluted sample of the E. coli solution after 3 h incubation.  




1:5 dilution of centrifuged and sonicated E. coli lysate obtained from 
one pellet from 50 mL E. coli sample solubilized in 10mL lysis buffer  
Lysate Pellet  1:5 dilution of centrifuged and sonicated E. coli lysate obtained from 
one pellet from 50 mL E. coli sample solubilized in 10mL lysis buffer 
Lysate 
Supernatant2  
Supernatant obtained from 20817 x g centrifugation of lysate 
centrifuged at 10 000x g  



































Pellet taken from centrifuged solution of 4 pellets, from 8mL of 
centrifuged supernatant, solubilized in 4 mL solubilization buffer  
Binding buffer  1:8 dilution of supernatant from 4 mL centrifuged solubilized solution.  
 
Amongst other bands we could see strong bands on the SDS-PAGE from aliquots obtained 
from the pellets, and weaker bands from aliquots obtained from the supernatant, at sizes 
around 38 kDa and 28 kDa (Figure 17). Bands at about 56 kDa also appear on the gel. The 
stronger bands in the pellet may be due to higher concentrations of the pellet sample 
compared to supernatant sample. The SDS-PAGE with the washing and eluted aliquots 
(image not shown) showed bands at around 38 kDa and 28 kDa. These bands were weaker 



























Figure 18: SDS-PAGE from protocol #4 using 1000 𝜇M L-rhamnose, 23℃ overnight, 10 pellets from expression 
step resuspended in 50mL lysis buffer, 30min sonication, centrifuged at 10000 x g and 20817 x g, without any 
purification step. Lysate supernatant and lysate pellet were the aliquots from the first centrifugation round. Soluble 





































Table 4: Content of the aliquots from Figure 18. Each sample lane was added 5 𝜇L sample buffer, 
2𝜇L reducing agent, 3𝜇L water and 10 𝜇L protein sample, and gave a total of 20 𝜇L applied to 
each well. 7 𝜇L Ladder was added.  
 
Name: Gel from 
protocol #4  
Aliquots on the SDS-PAGE obtained from 
Ladder SeeBlue Plus2 Pre-Stained Protein (Life Technologies, CA, 
USA) 
UI: Un-Induced Undiluted sample of the E. coli solution after 3 h incubation.  
I: Induced  Undiluted sample of the induced overnight E. coli sample from 
overnight incubation. 
Lysate Supernatant 1:30 dilution of centrifuged and sonicated E. coli lysate 
obtained from 10 pellets from 500 ml E. coli sample solubilized 
in 50 mL lysis buffer 
Lysate Pellet  1:30 dilution of centrifuged and sonicated E. coli lysate 
obtained from 10 pellets from 500 ml E. coli sample solubilized 
in 50 mL lysis buffer 
Solubilized 
Supernatant  
Sample taken after centrifugation of supernatant from lysate 
step 
Solubilized Pellet Sample taken after centrifugation and solubilization of pellet 
from supernatant lysate step 
 
Bands at the size around 38 and 28 kDa can again be seen in aliquots from both the 
supernatant and the pellet in figure 17. Bands at these sizes occur in most of the SDS-PAGE 
gels. Weaker bands at around 56 kDa can be seen after the first centrifugation in aliquots 
until lysate pellet, but is lost after the second centrifugation (Figure 18). By looking at this 
gel it may seem as though the whole LdAAP3 protein is not produced in large amounts. 
Small amounts can be seen on the gel, and stronger bands of fragments at 38kDa and 28 kDa 
seem to occur, which may indicate complication during expression yielding only fragments 
of the recombinant protein. Protein obtained from pellet and inclusion bodies are often 
undesirable because of problems occurring in attempts of renaturing the denatured proteins 




Figure 18: SDS-PAGE from protocol #9 with 500 𝜇M L-rhamnose, 23℃ overnight, 2 pellets from expression 
step resuspended in 20mL lysis buffer and 1%CHAPS, 20min sonication, centrifuged at 20 000 x g– then 3x 
165000 x g, no purification. Lysate sup and lysate pellet were taken from the fist centrifugation with 20 000 x g. 
Ultra 1 sup and pellet were aliquots taken from pellet from the first ultra centrifugation (165 000 x g) 
resuspended in lysis buffer and centrifuged at 165000 x g. Ultra 2 sup and pellet are taken from pellet from the 
second centrifugation (165000 x g) resuspended in lysis buffer and 1% CHAPS and centrifuged at 165000 x g. 
Ultra sup 3 is supernatant from the last centrifugation.  
 
When performing ultracentrifugations, the solution gets more purified. One centrifugation at 
40 000 x g may be enough since pellet from ultra 1 and ultra 2 seem to be similar. Continuing 
with the pellet from ultracentrifugation 1 may have been wise to do since we have relatively 
clean bands, at around the size of 56 kDa, 38 kDa and 28 kDa. Because we wanted to use this 
purified protein for polyclonal antibody production we wanted to see if we could purify the 
protein in the supernatant to avoid the difficulties of renaturation and refolding processes(82). 










































3.2.5 Codon usage 
The amino acid sequence of the Leishamnia donovani arginine transporter (LdAAP3) gene, 
obtained from NCBI, USA, was monitored for rare codons in the E. coli using the Rare 
Codon Calculator provided by the Molecular Biology Institute at the University of California, 
Los Angeles(83). The rare codons obtained from this analysis coded for the amino acids 
proline, icoleucine, leucin, and arginine. The ratio from Table 5 represents the abundance of 
the specific codon relative to the other codons that code for the same amino acid.  
 Each nucleotide sequence was translated using a translator program from ExPASy 
Bioinformatics Resource Portal (Switzerland), to see if these fragments could match the sizes 
of the fragmentations occurring of the recombinant LdAAP3 protein.   
Note that the fragments sizes starting from the Cter end do not contain the His-tag, 
because the His-tag is on the Nter end, and will therefore unlikely show as a band on the 
Western blots, but could show as bands on the SDS-PAGE and on the nitrocellulose 
membranes blotted with LdAAP3 recombinant protein incubated with infected sera. 
 
Table 5: The sizes of the proteins generated if translation were terminated due to the 
presence of rare codons.  
Rare 
codon 
Ratio Size of proteins from N-
terminal end (kDa) 
Size of proteins from C-
terminal end (kDa) 
CCC(Pro) 0.10 4,24 52,04 
ATA(Ile) 0,07 0,07 50,23 
CCC(Pro) 0.10 6,45 49,83 
ATA(Ile) 0,07 11,84 44,46 
CCC(Pro) 0.10 11,94 44,34 
CCC(Pro) 0.10 23,74 32,54 
CCC(Pro) 0.10 23,94 32,28 
CTA(Leu) 0,03 24,40 31,84 
ATA(Ile) 0,07 25,72 30,58 






Purification protocols were performed using Dynabeads His-tag isolation or His-trap HP or 
Ni-NTA columns. The LdAAP3 recombinant protein was often lost before elution steps 
during purification. Different attempts like changing imidazole concentrations in the buffers 
and eluting using pH were tested to see if more of the target protein would be obtained.  
 
3.3.1 Imidazole concentrations 
How high the concentration of the imidazole before the protein loos their binding affinity to 
the immobilized metal ion seems to vary between the different purification methods. In 
protocol #3 (Figure 17) using 1DynaBeads solution, weak bands were seen in the eluted 
aliquot using 300mM of imidazole (image not shown). During protocol #9.2 (Figure 24) 
using HisTrap column with 1HisTrap buffers, almost all of the proteins loos their binding 
affinity to the column when washing 2 buffer was added containing 75mM imidazole. When 
using the Ni-NTA column the target protein loos their binding affinity to the column when 
using NPI-250 buffer containing 250mM imidazole (Figure 25). A lot of bands were seen in 
the eluted aliquots from protocol #7, when using 2DynaBeads solutions with 300mM 
imidazole (image not shown). The different protocols cannot be directly compared to each 
other. 
 
3.3.2 Denaturation conditions 
In case the LdAAP3 recombinant protein did not elute from the column during purification, 
buffer E (8M UREA, 100mM Tris-base, 100mM NaH2HPO4 ) from the Ni-NTA Superflow 
buffers with denaturing conditions was used as the final flow through solution during 
protocol #12 (Figure 25). If you look at Figure 25, you could see a weak band in the FT-BE 
well of the SDS-PAGE at sizes about 56 kDa. When looking at the Western blot, from Figure 
25, of this aliquot it did not show any proteins. Using denaturing buffers seem to elute the 
remaining LdAAP3 protein. This may indicate that some of the LdAAP3 recombinant 
proteins have strong binding affinity to the column. 	
During protocol #11, denaturing conditions using 2HisTrap buffers with decreasing 
pH was tried out (Figure20). Most of the proteins seemed to let go of the column at pH 6.3 
when using 2HisTrap – washing buffer 1, though weak bands can be seen under washing 
buffer 2 and eluted 1 (Figure 20). Elution by acidic pH was not continued because target 
proteins were not obtained during pH elution. In the same protocol many protease inhibitors 
were added to see if this could help stop the fragmentation of the ORF. We did not see 
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remarkable changes in the bands and still had fragments compared to other attempts without 
the addition of these inhibitors. This can further support the theory that the fragments 
obtained are not due to degradation of the ORF LdAAP3 recombinant protein, but may rather 
be due to problems during translation of the whole LdAAP3 ORF, yielding problems in 




Figure 20: This gel is from protocol #11 with 500 𝜇M L-rhamnose, 23℃ overnight, 2 pellets from expression 
step resuspended in 15mL lysis buffer and protease inhibitors, no sonication, centrifuged at 20817 x g, 
purification with His-Trap column using 2HisTrap buffers with denaturing conditions and pH elution.  
 
 
3.3.3 Testing SDS-PAGE limits 
Because other purification steps were not completely successful, SDS-PAGE gels were used 
to separate the proteins further. Small amounts of the LdAAP3 recombinant protein seemed 
to be obtained. Filtration of the purified solution was performed to increase the concentration. 
To further increase the amount target protein obtained per well, the maximum amount of 
sample loaded in each well was tested. Increasing amounts of concentrated washing 3 flow 
through from protocol #9.2 was added. 5 𝜇L sample buffer and 2 𝜇L reducing agent was 



















































Figure 21: SDS-PAGE with wells containing increasing amount of washing 3 flow through aliqotes from 
protocol #9.2. Each well was added 5 𝜇𝐿 more sample than the latter. Lane 1: un-stained ladder. Lane 2: pre-
stained ladder. Lane 3: 10 𝜇𝐿 sample in a total of 20 𝜇𝐿. Lane 4: 13 𝜇𝐿 sample in a total of 20 𝜇𝐿. Lane 5: 
18 𝜇𝐿 𝑠𝑎𝑚𝑝𝑙𝑒 in a total of 25 𝜇𝐿. Lane 6: 23 𝜇𝐿 sample in a total of 30 𝜇𝐿. Lane 7: 28 𝜇𝐿 sapmle in a total of 
35 𝜇𝐿. Lane 8: 33 𝜇𝐿 sample in a total of 40 𝜇𝐿.  
 
 
3.4 Quantification of protein  
Before immunization of the rabbits for production of polyclonal antibodies against the 
LdAAP3 recombinant protein, we had to quantify the protein. After running SDS-PAGE and 
Western blots it was decided to use concentrated aliquot washing 3 from protocol #9,2 
because it had relatively few bands on the gel and contained the LdAAP3 recombinant 
protein confirmed by His-tag binding on the Western blot (Figure 24). Dilutions of the 
concentrated washing 3 solution were added on a SDS-PAGE to find a dilution with the 
optimal amount of proteins. Calculations were done for target LdAAP3 recombinant proteins 























Figure 22: SDS-PAGE with two different ladders and decreasing amounts of concentrated washing 3 samples 
containing LdAAP3 recombinant protein. Rectangles are drawn for quantification using ImageJ. Dilutions in 
the following lanes from 1-6 was: 1:1.5, 1:2, 1:5, 1:10, 1:20, 1:30 respectively, in a total amount of 35 𝜇L. 7 𝜇L 









Figure 23: Shows the profile plot of the marked ladder(#7) from Figure 21. The yellow peak indicates the fifth 
band on the ladder, the peak of interest, which had a size of 50kDa and known amount of 750ng.  
 
Because the sample is not completely purified, the gel consists of many bands. We had to 
choose the band of interest by counting the peaks against the bands from the gel, and 























































peak on the profile plot from Figure 23 represents one band in one marked rectangle. We 
have seven marked rectangles. A higher peak means darker bands, and wider peaks gives 
bands with bigger size range on the gel.  
In each rectangle we are only interested in the bands at size around 32 kDa and 26 
kDa. For each profile plot from a single rectangle the two peaks representing these two bands 
were marked, and showed two areas/arbitrary values. When marking the peak from the 
profile plot it turned yellow and its arbitrary values came up in the Results Window. These 
values are used to calculate the amount of protein (equations found in methods section 2.5.1).  
 
Table 6: Values of peaks chosen for N1 bands and their calculations. Arbitrary number 





Amount protein in 
ng 
Amount protein in 𝝁𝒈 per 
500𝝁l 
1 7594,50 430,75 9,23 
2 7346,50 416,69 11,91 
3 4732,11 268,40 19,17 
4 2311,34 131,10 18,73 
5 1294,21 73,41 20,97 
6 773,26 43,86 18,74 
7 
standard/ladder  
3778,234 - - 
 
Table 7: Values of peaks chosen for N2 bands and their calculations. Arbitrary number 





Amount protein to 
ng 
Amount protein in 𝝁𝒈 per 
500𝝁l 
1 12779,35 724,84 15,53 
2 12321,57 698,87 19,97 
3 8316,67 471,72 33,69 
4 4286,55 243,13 34,73 
5 3187,38 180,79 51,65 
6 2002,01 113,55 48,53 
7 Ladder (50 kDa) 3778,234 - - 
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3.5 Raising anti-LdAAP3 polyclonal antibodies 
For an optimal immunization regime BioGenes GmbH (Germany) recommended to prepare 
purified LdAAP3 protein in a concentration of 100-200𝜇𝑔/500𝜇L. Due to low protein 
concentrations obtained of the LdAAP3 recombinant protein, it was decided to use the 
highest dilution (1:1.5). 23,33𝜇L solution of purified LdAAP3 recombinant protein from 
washing 3 aliquots obtained from protocol #9.2 was loaded per well in a total of 35𝜇L with 
buffer added. The gel bands at size 26 kDa (N1) and 30-32 kDa (N2) were cut out of the gel, 
and were sent to BioGenes GmbH in Germany for immunization in rabbits.  
 
3.6 Protein blotting 
3.6.1 Detecting the His-Tagged LdAAP3 recombinant proteins  
Western blots were performed in an attempt to localize the His-tagged E. coli Lemo 21 
LdAAP3 recombinant proteins in order to decide which aliquot to continue with. The 
decision was based on purity of the solution and whether it contained the His-tagged 
LdAAP3 recombinant proteins.  
Figure 24: The SDS-PAGE on the left and a Western blot to the right; following the protocol #9,2 using 500 𝜇M 
L-rhamnose, 23℃ overnight, 5 pellets from expression step resuspended in 15mL lysis buffer, 20min sonication, 




















































Figure 24 shows a Coomassie stained SDS-PAGE compared with a Western blot where the 
same aliquots were applied, which enables localization of the LdAAP3 proteins containing 
the His-tag. His-tags cut off from the protein may result in the LdAAP3 recombinant protein 
not showing on the nitrocellulose membrane.  
We had difficulty revealing the whole ORF protein (56 kDa) with the Western blot. 
Proteins at the size of 56 kDa could be found weakly in aliquot number 6 (Wash 1) on the 
Western blot from Figure 24. Stronger bands of smaller fragments at the size 38 kDa and 
above and below 28 kDa are repeatedly seen. Because aliquot number 6 (wash 1) contained a 
lot of other proteins, we decided to use aliquot number 8 (wash 3) with fragments at the size 
of about 32 kDa and 26 kDa for polyclonal antibody production.  
 
3.6.2 Blotting LdAAP3 recombinant protein on nitrocellulose membrane  
Production of more LdAAP3 recombinant protein was made following protocol #12 and 
using the Ni-NTA Superflow column. The nitrocellulose strips were blotted with an equal 
mix (50:50) of lysated sample from NPI-20 flow through and NPI-250 flow through. A 
1:2000 ratio of AP conjugated HisG Epitope Tag primary antibody, (mouse/IgG2a, Thermo 
















Figure 25: Western blot (left) and SDS-PAGE (right) from protocol #12, using 500 𝜇M L-rhamnose, 24℃ overnight, 
20 pellets from expression step resuspended in 34mL NPI-10 buffer, 4 min sonication, centrifuged at 10007 x g, and 
purification with Ni-NTA column.  20 𝜇𝑙 of each sample was loaded per well.  
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The new column and buffers used seemed to be more successful in purifying the ORF 
LdAAP3 recombinant protein. When looking at the aliquot containing FT-NPI-20 and FT-
NPI-250 on the SDS-PAGE to the right, bands at the size of about 56 kDa can be seen 
(Figure 25). The FT-NPI-250 was relatively purified, indicating a successful production of 
the recombinant protein found at a band at about 56 kDa that most likely is the whole ORF 
LdAAP3 recombinant protein, in a relatively purified state. These bands were not verified by 
AP conjugated antibody binding to the His-tag and are not seen on the Western blot (to the 
left). Several bands on the Western blot can be seen. Strong bands at the size of about 38 kDa 
and 28 kDa is also seen here.  
	
3.6.3 Testing sera from Leishmania infected and non-infected individuals  
Using the nitrocellulose membrane strips blotted with the LdAAP3 recombinant protein from 
the lysated sample of the flow through NPI-20 and NPI-250, sera from different types of 
Leishmania infections and different hosts were tested. This was done to see if antibody 
produced from infected subjects could bind to the LdAAP3 recombinant protein that was 
















Figure 26 : The NPI-20 and NPI-250 blotted nitrocellulose strips were added sera from mice infected with 
L.amazonesis and incubated overnight, Donkey anti-mouse was used as the secondary antibody, Odyssey 
blocking buffer in a total of 2 mL was used. Strips were washed three times with PBST. Marked boxes indicate 
bands occurring at the size of 56 kDa, 45 kDa, 32 kDa, 30 kDa and 12 kDa.  
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1:100, 1:500 and 1:1000 dilutions of sera in 2 ml blocking buffer were tested in this protocol. 
No serum was applied to strips number 13, and was the negative control against the contents 
of the buffers in the protocol. Strip 13 (negative control) showed no bands or background. 
Dilution 1:100 showed many bands, but with a lot of background. Strips 11 and 12 displayed 
less background, but weak bands.  
Bands can be found at around 56 kDa, 45 kDa, 32 kDa, 28 kDa, and around 12 kDa. 
These band sizes can be found on the Western blot and SDS-PAGE from Figure 25, and 
indicate that the proteins produced from LdAAP3 recombinant expression seem to have 
epitopes that match the antibodies generated in Leishmania amazonensis infected mice.  
These strips were incubated with sera overnight in 4℃. Overnight incubation gives 
time for albumin, other proteins and antibody with little affinity, to bind to the strips. Shorter 




Figure 27: The strips were added sera from mice infected with L.amazonesis and healthy mice (BALB/c, 40 
days, male) as negative controls and incubated for 1 and 2 hs. Donkey anti-mouse was used as the secondary 
antibody, Blocking buffer with 0.1% Nonfat-dry milk was added in a total of 3 mL. Strips were washed four 
times with PBST and once with PBS. Strip 21(negative) was not added sera. Trip 25 was added sera from 
healthy mouse in a dilution of 1:100. Strips 22-24 from the 2h incubation contained dilutions of 1:100, 1:200 
and 1:500 respectively. Strips from 33-35 from the 1h incubation contained dilutions of 1:100, 1:200 and 1:500 
respectively. 
 
1h incubations seems to be too little due to almost no bands occurring on the strips. A weak 
band could be seen in the black and white image at around 49 kDa on strips number 33. For 
the strips incubated for 2 hs the bands show at sizes around 56 kDa, 49 kDa, 38 kDa and 30 
33			34				35	33			34				35	
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kDa. Dilution 1:200 and incubation for 2h seem to obtain nice bands with less background. 
Negative and healthy controls did not show any bands, which may indicate that the bands 
showing on the strips incubated with infected sera can be due to the Leishmania infection. 
Antibodies generated from infection seem to match the proteins blotted on the nitrocellulose 


















Figure 28: These strips were incubated with human sera infected with L.infantum chagasi and dog sera infected 
with L. donovani, and incubated for 1 and 2 hs. Goat anti-human IgG was used as the secondary antibody for 
the strips incubated with human sera. Blocking buffer with 0.1% Nonfat-dry milk in 3mL solutions was used. 
The strips were washed four times with PBST and once with PBS. For the 2h incubation, strip 29 was incubated 
with sera from healthy human in a dilution of 1:100. Strips 26-28 contained dilutions of 1:100, 1:200 and 1:500 
respectively. For the 1h incubation with human sera, strips 36-38 contained dilutions of 1:100, 1:200 and 1:500 
respectively. 
 
3 different incubations were done for samples added with human sera. The first incubation 
was with sera from a patient infected with L. infantum. The second incubation was with goat 
anti-human IgG peroxidase, which binds to the primary antibody from infected human sera. 
The third incubation was with anti-goat IRD 680 (Odyssey-Licore), which binds to the 
secondary antibody produced in and is revealed in the Odyssey scanner.  
The bands from the 1h incubation with human sera were better than the 2h incubation 
and showed slightly weak bands around 38 kDa for strip 36 and 37. Wrong secondary 
antibodies were used for the dog samples and are the reason for the empty bands. 
Several attempts were done for human sera. In these attempts (image not shown) the 
strip incubated for 1h with 1:100 dilution of sera from healthy human showed bands around 
62 kDa and again below 28 kDa. Sera from infected human diluted in 1:200 showed bands in 




























This protocol was done to get an indication of what dilutions to use when testing the sera 
from LdAAP3 recombinant protein immunized rabbit against the LdAAP3 Lemo21 produced 




















produced recombinant protein bind to the sera from rabbit produced from the LdAAP3protein, which again will 
bind to the AP conjugated secondary antibody. Dilutions:	1	–	1:500,	2	–	1:1000,	3	–	1:2000,	4	–	1:4000,	5	Pre-
immune	1:1000.	
	
Strips number five containing sera from rabbit before injection of the LdAAP3 protein show 
a lighter band indicating that there probably is no antibody produced in this sera that is able 
to bind to the secondary antibody conjugated with alkaline phosphatase. A colorimetric 
detection is seen in purple when the LdAAP3 antibody from rabbit, bound to the LdAAP3 
protein, is added BCIP/NBT. The dilutions on the other hand were not as easy to part from 
each other although strip number 4 is slightly lighter than the rest. But it is clear that the 
rabbit immunized with LdAAP3 recombinant protein produces antibody that binds to the 











3.6.5 Testing anti-LdAAP3 polyclonal antibodies against E. coli produced LdAAP3 proteins 
Nitrocellulose membrane blotted with LdAAP3 recombinant purified solution from the Ni-
NTA lysis and purification step was used and incubated with sera from rabbit immunized 
with recombinant LdAAP3 protein. Rabbit number 71 and 72 were injected with proteins at 
the size of around 32kDa, called N1. Rabbit number 73 and 74 were injected with proteins at 
the size of about 26 kDa, called N2. AP conjugated HisTag secondary antibody was used for 



















Figure 30: LdAAP3 blotted nitrocellulose strips were incubated with sera from rabbit number 73 of N2 in 
different dilutions. Sera incubated on strip 70 was obtained before immunization with LdAAP3 recombinant 
protein and functioned as a control. Dilution ratios: 70 – 1:1000, 71 – 1:2000, 72 – 1:4000, 73 – 1:5000, 74 – 








70        71       72         73       74 
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When comparing the ratio used in the Dot-blot and sera obtained from rabbit 73, it was 




Figure 31: LdAAP3 blotted nitrocellulose strips incubated with sera from pre-immune and immunized rabbit 
number 70, 71, 72, 73 and 74, in a dilution of 1:4000 of sera and blocking buffer (TBS + 5% BSA).  
	
Detection of antibodies are produced by colorimetric detection when adding BCIP/NBT to 
the AP conjugated secondary anti-rabbit antibody that could bind to the primary antibody 
from the sera of the LdAAP3 injected rabbit, which again could bind to the recombinant 
LdAAP3 protein blotted on the nitrocellulose membrane.  
 Clear bands can be seen at around 56 kDa and around 26kDa (Figure 30). On Figure 
31, clear and strong bands also occur at around 56 kDa along with other strong bands at the 
size of about 32 kDa and 26 kDa. Rabbits immunized with N1 (26 kDa) and N2 (32 kDa) 
proteins seem to detect bands at bigger and smaller band sizes than the size of the protein 
they were immunized with. Several bands can also be found above 56 kDa which may be due 
to conjugation. Strip number 8 (immunized N2 rabbit number 74) had many bands, and may 
indicate a strong immune response. Pre-immune strips from rabbit 71, 72 and 73 showed 




















































3.6.6 Testing SLA and recombinant LdAAP3 against anti-LdAAP3 antibody using ELISA 
Purified recombinant protein and soluble Leishmania amazonensis antigen was tested, and 
visualized by goat anti-rabbit IgG-Horseradish peroxidase (GE Healthcare, UK) secondary 
antibody in a ratio of 1:2000.  
 
Figure 32: Wells were coated with purified recombinant LdAAP3 protein before anti-LdAAP3 polyclonal 
antibodies were added as primary antibody, and goat anti-mouse Horseradish peroxidase (GE Healthcare, UK) 
was used as secondary antibody to be able to measure the absorbance.  
 
 
Figure 33: Wells were coated with purified recombinant LdAAP3 protein before anti-LdAAP3 polyclonal N2 
antibodies were added as primary antigen, and Horseradish peroxidase (GE Healthcare, UK) was used as 









































Looking at the graphs showing the N1 and N2 titers when using purified recombinant 
LdAAP3 protein as the antigen, a clear difference can be seen between the pre-immune and 
immune sera. This indicates that the animals have produced antibodies against the 
recombinant LdAAP3 recombinant protein, and that there is some specificity for the antigen.  
 
Figure 34: Wells were coated with soluble L. Amazonensis antigen (SLA) before anti-LdAAP3 polyclonal N1 
antibodies were added as primary antigen, and Horseradish peroxidase (GE Healthcare, UK) was used as 
secondary antigen to be able to measure the absorbance. 
 
 
Figure 35: Wells were coated with soluble Leishmania amazonensis antigen (SLA) before anti-LdAAP3 
polyclonal N2 antibodies were added as primary antigen, and Horseradish peroxidase (GE Healthcare, UK) 











































Figure 36: Wells were coated with soluble L. Amazonensis antigen (SLA) before anti-LdAAP3 polyclonal N1 
antibodies were added as primary antigen, and Horseradish peroxidase (GE Healthcare, UK) was used as 
secondary antigen to be able to measure the absorbance. 
 
When testing N1 and N2 serum against soluble Leishmania amazonensis antigen the results 
show that antigen in the serum had low affinity for L. amazonensis. For N1, only animal 72 
produced antibodies. For N2, only animal 74 produced antibodies. In general, sera from N1 
animals showed increased titers compared with the pre-immune animals. Animal 71 had 
higher titers than animal 72. Titers for N2 animals showed high affinity for animal 74, but 

































4. DISCUSSION  
 
4.1 Amplification of the LdAAP3 ORF 
Overexpressing membrane proteins can be challenging as each protein behaves in an 
individual and unpredictable way. Though choosing a specific host and plasmid with the 
desired qualities can give a positive advantage, it is difficult to foresee the amount of protein 
production or whether the recombinant protein will be soluble, or maintain its proper 
conformation by correctly folding (84). In earlier studies, overexpression of 300 membrane 
proteins were conducted in E. coli, but did not show any correlation between protein specific 
parameters, i.e. size, hydrophobicity or number of transmembrane helices, and the 
expressability. Generally, smaller proteins tend to be better expressed than larger proteins 
(85).  
Because the whole LdAAP3 protein consists of 11 transmembrane domains (37), and 
is assumed to be toxic for the E. coli, we chose to use competent E. coli Lemo21(DE3) for 
transformation and expression for the Cter LdAAP3 protein and the ORF LdAAP3 protein, 
with 2 and 11 transmembrane domains respectively. 
Although the Lemo21 strain is a host more suited for toxic proteins, it utilizes lac 
promoters, which are known to be leaky (46). This means that the transcriptional control of 
the operon is not completely effective and there can be some basal transcription without the 
addition of inducer because the promoter is never completely off (86). This can be observed 
in Figure 18, where expression of proteins at a size of 38 kDa occurs in the un-induced 
aliquots. This leak could lead to incomplete repression of the protein expression, which could 
further lead to plasmid instability or loss. Because of this, the culture could be overgrown by 
E. coli that no longer render the plasmid, or not grow at all. Titrating the amount L-rhamnose 
added to an optimal level of T7 lysozyme production to inhibit enough of the T7RNAP is 
therefore essential when producing toxic proteins. Using a more tightly regulated promoter or 
adding 1% glucose to suppress the induction of lac promoter in the presence of lactose could 
help eliminate these problems and give a better regulation of expression (46, 54, 87, 88). Fine 
tuning expression kinetics can be done by lowering the amount IPTG added (89), and 





4.2 Expressing the LdAAP3 ORF recombinant protein with 11 transmembrane domains 
E. coli is a much used host for expression of recombinant proteins. The main reason for this 
is its well-known genetics, transformation efficiency, low cost and cultivation simplicity (53). 
The gene of interest is cloned in an expression vector, transformed into a host where 
production of the gene of interest is induced, the host cell is then lysated to free the translated  
gene, which then can be purified. Although the theory is simple, expressing a pure 
unfragmented recombinant protein is complicated. The number of choices ranging from 
which vector and host to use to methods of purification and different concentrations to use, 
are immense and finding the perfect combination at once is difficult and therefore often 
requires a great deal of trial and error (84). Incorrect translations, different protein folding, 
degradation, and premature termination may give us different variants of our target protein 
(64). Possible explanations to the challenge we meet during expression are explained in the 
following.    
 
4.2.1 Toxic genes 
To productively utilize the host for expression, knowing the genetics of the bacterium is an 
important factor, especially when expressing toxic proteins. In the very beginning of this 
project expression of the ORF was attempted using E. coli Bl21(DE3) Star without success. 
When analyzing the nucleotide sequence of the L. donovani AAP3 protein, we saw that it 
contained 11 transmembrane domains (Figure 15). We concluded that it might be a toxic 
protein for the expression vector and therefore chose E. coli Lemo21 as the host. To find out 
whether the recombinant protein is toxic for the E. coli, we could have monitored and 
compared the cell growth of the recombinant strain and an empty-vector.  
 
4.2.2 Plasmid stability 
A central problem when expressing highly toxic genes is the instability of the plasmid during 
the growth phase. Cells without the pET151/D-TOPO plasmid inserted can rapidly take over 
the culture because of their physiological advantages (49). This can explain the low 
production of our LdAAP3 recombinant protein leading to challenges during purification. 
Adding expression of genes that could lead to cell death in plasmid-free cells could aid the 
survival of the cells containing plasmid. Harboring the lysozyme gene may sometimes not be 
enough to prevent toxicity, and the plasmid carrying the toxic gene cannot be maintained in 
the host. This can be avoided by growing E. coli without the T7 gene, to then induce the host 
in mid-log growth face by delivering the T7 by infection (53).  
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Another attempt to avoid this toxicity is to rout the expression of the recombinant 
protein to the extracytoplasmic space by fusing a leader peptide to the protein(84). Adding a 
lac promoter downstream of the cloned gene could lead to less expression of the toxic protein 
due to less expression of T7RNAP. Introducing more T7 promoters in the host plasmid would 
lead to competition with the T7 promoter in front of the toxic gene, which could lead to 
decreased basal expression.  
 
4.2.3 Copy number of plasmid 
Manipulating the plasmid-copy number before induction can be critical for E. coli survival, 
and should have been done for our experiments. Lowering the plasmid number before 
induction may enhance E. coli survival prior to the expression. Regulating the expression of 
genes controlling expression of vector can do this. Increasing the plasmid-copy number by 
thermal control, or using T7-based expression vectors that increases their plasmid copy 
number when arabinose is added may increase the expression of the recombinant protein. 
(53). The best expression system for toxic proteins would be completely repressed until 
induction, with a titreable protein production (46). 
 
4.2.4 Resistance markers 
In our case the ampicillin and chloramphenicol resistance markers are sitting on two different 
plasmids, containing genes for the T7 promoter and T7 lysozyme respectively (Figure 11).  
Chloramphenicol is important to maintain a selective pressure to keep the plasmid 
coding the T7lysozyme inside the Lemo21 E. coli (49). The resistance mechanism of E. coli 
to ampicillin and chloramphenicol, though not completely the same, is to enzymatically 
degrade the antibiotic. After a couple of hs, the antibiotics can be depleted and growth of E. 
coli without these markers could occur (84). Ampicillin concentration at 100𝜇g/mL is often 
used, as done for our experiments. Too high levels of antibiotics can lead to less production 
of the recombinant protein due to energy being focused on getting rid of the antibiotics (53). 
Chloramphenicol binds reversibly to the ribosome and obstructs the protein synthesis in the 
E. coli. Using chloramphenicol as a resistance marker may thus affect the production of 
recombinant protein. To test for plasmid stability and how well the resistance markers have 
worked, it could have been wise to do a plasmid stability test. This could give us a better 
indication on whether the bacteria we use for expression actually contains the plasmids of 
interest. When picking colonies on the agar plate we made sure to get small and isolated 
colonies. Colonies with plasmids where mutations have occurred, tend to form bigger 
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colonies even though IPTG is added. This can be explained by the excess energy for growth 
when recombinant protein is not expressed. Small colonies on the other hand, often contain 
plasmid, and do not grow into bigger colonies because energy is used for production when 
IPTG is added.  
Using elevated levels of antibiotics or using tetracycline as a resistant marker, with 
efflux active resistance mechanism, may have increased the chances of maintaining the 
plasmid inside the host (87).  
 
4.2.5 Host selection 
For expression of soluble proteins larger than 10-50 kDa, yeast or baculovirus can be more 
preferable host compared to E. coli (45). Using an E. coli host can be particularly challenging 
due to its limited capacity for posttranslational modifications allowing proper folding of the 
protein (45). However, researchers have experienced modest success when using yeast or 
baculovirus as hosts (90).  
Due to challenges during production of the ORF LdAAP3 in E. coli, it may have been 
better to use yeast with improved folding and posttranslational modifications that may allow 
better expression (45). Shaked-Mishan et al. (2006) along with other scientist groups has 
been successful in expressing LdAAP3 in Saccharomyces cervisiae yeast (35, 37).  
 
4.2.6 Standardization of L-rhamnose concentration and incubation time after induction  
Producing the ORF protein does not benefit the E. coli host, and its production will probably 
be harmful for the bacterial cells. When adding L-rhamnose the rhamnose promoter will be 
activated and promote synthesis of T7lysozyme, which is an inhibitor of T7RNAP(49). Less 
expression of T7RNAP can lead to less activation of the T7promoter that sits right in front of 
the ORF sequence. The result is less recombinant protein expressed, which can presumably 
lead to increased cell survival. Lowering the expression by changing the concentrations of L-
rhamnose and lowering the temperatures could aid the challenge regarding the toxicity. 
During our experiments we used 0-2000 𝜇𝑀 L-rhamnose. 
 When testing optimal L-rhamnose concentration and incubation time the un-induced 
(UI) bands were week, as expected (Figure 16). This could be explained by the lack of 
inducer IPTG, but we cannot exclude that this could be due to a shorter incubation time than 
the rest of the aliquots. The best samples to compare would be UI (2000𝜇M) and induced 
aliquot number 5 (2000𝜇M), incubated for 3 and 4 hs respectively. An increase in band 
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intensity for induced aliquot 5 can be seen in Figure 16, confirming the effects of the inducer. 
Further, the effect of T7 lysozyme could be seen in aliquots 1, 6 and 11 (Figure 16), which do 
not contain L-rhamnose. Band 1 and 6 show lower band intensities. This may indicate less 
expression without L-rhamnose, which can be explained by the toxicity of the protein. It 
could seem that after enough amount of time of incubation a limit in the expression is 
reached. This can be observed for the 24h incubated aliquots, where the bands seem to be 
equally strong despite the different amounts of L-rhamnose added (Figure 16). Because of 
this we decided to continue with induction for 16-18h. The band intensity seem to increase 
with higher levels of L-rhamnose and longer incubation time. During our experiments we 
chose to use 500𝜇𝑀 and 1000 𝜇𝑀 of L-rhamnose, without seeing any big difference in the 
expression of the recombinant LdAAP3 protein.  
The same test could have been repeated with different temperatures to see the effects 
of temperature in different L-rhamnose concentrations. Although we did small scale-
production, we could also have done micro-scale production. This would allow us to test a 
high number of culture conditions and save time while doing so. We concluded that adding 
IPTG induces the production of protein and that increasing the levels of lysozyme with L-
rhamnose affects the expression in a positive way.  
 
4.2.7 Temperature 
Changes in temperature ranging from 20 to 30 ℃, were done to se if it could affect the 
production of the LdAAP3 recombinant protein. Lower protein concentrations, and slower 
rates of production, could improve transcription and translation and favor proper folding of 
the proteins (85, 89). It can decrease aggregation, giving us more of the protein in the 
supernatant (84). Lower temperatures during growth of E. coli generally give improved 
biological activity and higher yields of the recombinant protein (91, 92). Using too low 
temperature might reduce synthesis and result in to little protein yields (84), but lowering the 
temperature during expression has also shown to improve the solubility of the proteins (93). 
This occurs because hydrophobic interactions that form inclusion bodies are temperature 
dependent (93). Higher temperature means higher entropy and more inclusion body 
formation. These temperature changes may also affect L-rhamnose and therefore also affect 
how much the T7RNAP may be inhibited (49). Optimal expression temperature will vary and 
depend on the protein, amount L-rhamnose added, and incubation time.  
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 Although we did just a few expressions with higher temperature than 24℃, when 
running an SDS-PAGE at 37℃ (images not shown), the bands seem to be slightly weaker. 
Experiments using a lot higher and a lot lower temperatures could have been conducted to 
compare the effects of temperature utterly.  
It would have been interesting to add a GFP (green fluorescent protein) gene in the 
vector to be able to use flow cytometry to get a more reliable estimation of the LdAAP3 
production (49). This would allow us to count the amount of cells that are able to express our 
protein, making it easier to analyze the results when changing temperature, incubation time 
and L-rhamnose concentration (49).  
 
4.2.8 Lysis and Centrifugation  
Though sonication normally does not break up primary structure of proteins, it may lead to 
unfolding and enhanced aggregation because of the heat generated and mechanical forces 
produced (94). Long sonication may result in more cells lysated generating more free 
organelles, nuclei and lipids in the solution. This crowded solution may affect the purification 
by sterically standing in the way for the His-tagged proteins to bind when performing IMAC, 
which may be an explanation to our problems during purification.  
 During centrifugation, cell organelles normally are found in the pellet, while soluble 
proteins remain in the supernatant. Knowing that the LdAAP3 protein is an 11 domain 
transmembrane protein, it is likely that this protein will aggregate and precipitate from 
aqueous solutions when centrifuged due the size and its hydrophobic regions that may be 
exposed when the protein is free from the cell membrane (95). Some of the protein may still 
be attached to some lipids from the cell membrane, which also may lead to accumulation and 
aggregation. In our experiments we found the LdAAP3 recombinant protein both in the 
supernatant and in the pellet. Whether our protein is in the pellet due to inclusion body 
aggregation, or because of its size and that it is bound to the cell membrane is hard to 
determine. Though if only in the pellet, the protein might be integrated in the cell membrane 
retaining its natural folding. Refolding the inclusion bodies on the other hand, could affect 
the proteins activity and conformation. To avoid this problem, continuing with the protein in 
the supernatant was chosen, although more of our protein seemed to be in the pellet (93, 96).  
 
4.2.9 Inclusion bodies formation 
The environment in the E. coli host is different from the environment in the Leishmania 
parasite. The recombinant protein can be affected by this and cause protein instability and 
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aggregation. Unbalance in aggregation and solubilization of the protein can lead to inclusion 
body formations (84). 
 During high levels of expression the cytosol can become crowded, and can saturate 
the quality control mechanism of the cell leading to misfolding.  
 Incorrect disulfide bond formation can lead to the generation of inclusion bodies. The 
AAP3 protein contains 10 cystin amino acids that may be bale to generate disulfide bindings, 
and lead to formation of inclusion bodies. Increasing the solubility may aid this problem. 
This can be done by co-expressing chaperon molecules together with the recombinant protein 
(85, 91) or fusing the recombinant Cter or Nter part of the protein with a soluble fusion tag. 
Molecular chaperones utilize cycles between ATP binding and hydrolysis to facilitate the 
folding of the protein (97). Optimization still has to be done, as no single tag appears to work 
for all recombinant proteins (45, 56). 
 
4.2.10 Results from SDS-PAGE analysis  
SDS-PAGE was used to give us an indication on how the different changes in temperatures, 
incubation time, centrifugation and L-rhamnose concentration could effect the production of 
the LdAAP3 recombinant protein. No matter what changes we made, fragmentation of the 
LdAAP3 recombinant protein seem to occur and we were not successful in completely 
purifying the protein using IMAC. When comparing all the different gels and trials with 
changes in the protocol, the SDS-PAGE from protocol #12 (Figure 25) using Ni-NTA buffers 
and columns seem to be most successful. This experiment yielded a relatively purified 
solution (FT-NPI-250) containing bands at the size of about 56 kDa and 26 kDa. When 
comparing this protocol with similar protocols with same temperature and amount L-
rhamnose added the major difference seem to be the sonication time. Sonication with Ni-
NTA protocol was used for 4 min compared to other protocols with 15-30 min sonication. 
This could imply that production of the ORF LdAAP3 protein may be occurring in the 
different protocols but the lysation has been conducted for too long rendering a crowded 
solution, making it difficult for the His-tag proteins to bind to the IMAC.  
 All aliquots should have had as similar concentrations and conditions as possible, 
with preferably only one difference from each other, when comparing them. For instance 
comparing the band intensity of the uninduced bands, with 3h induction, would naturally 
have weaker bands than the induced bands with overnight incubation. The uninduced sample 
should have been incubated using the same settings for as long time as the induced aliquots to 
get a more accurate observation on how the IPTG affected the induced aliquots. 
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Growing a culture with an empty vector inserted and using the same conditions as the 
culture with the plasmid would have been possible to do in order to compare the differences 
between the two cultures. This may also allow us to eliminate some of the bands from other 
protein production in E. coli to the LdAAP3 recombinant protein bands.  
 
4.2.11 Codon usage 
When expressing genes in another host like E. coli significant differences in codon usage 
between the two organisms can interfere with the translation because one or more tRNAs 
could be rare or lacking and lead to fragmentation (51). tRNA depletion can lead to improper 
translation leading to wrong construction of the different amino acid or even termination of 
translation that could lead to the production of fragments. This seems to occur for our 
recombinant proteins. Changes like these may also affect the proteins activity. To avoid this 
problem it may help to increase the availability of underrepresented tRNAs (84, 98). This can 
be done by overexpressing genes encoding the rare tRNAs (99).  
When analyzing the rare codons of E. coli and the size of the protein fragmentations it 
may have produced, we could see some fragments matching with the sizes of the bands found 
when running several test of our recombinant protein, using nitrocellulose LdAAP3 
recombinant protein blotted membranes. When comparing the Western blot from Figure 24 
and 25, bands at the size of about 26 kDa and 12 kDa occur. The same sizes could be found 
in Table 5 showing fragment sizes starting from the Nter. Finding these bands on the Western 
blot can be logical because the Nter contains the His-tag.  
When comparing the bands obtained from LdAAP3 recombinant protein blotted 
nitrocellulose strips incubated with sera from infected subjects, bands at around 49, 45, 32, 
30 and 12 kDa seem to reoccur. These protein sizes are also found in Table 5 showing the 
protein fragment sizes starting from the Cter end. Bands at the size of 31 kDa and 12 kDa can 
be found from LdAAP3 blotted nitrocellulose strips incubated with sera from immunized 
rabbit. These sizes can also be found in Table 5 showing fragments generated from the Cter 
end. The Cter end does not contain His-tag but can be detected by antibody affinity against 
epitopes.  
The LdAAP3 blotted nitrocellulose strips incubated with sera from immunized rabbit 
also showed bands at the size of around 26 kDa and 30 kDa (figure 30). Summed together 
these two fragments gives the whole LdAAP3 size at about 56kDa. 
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In theory codon bias could affect the expression and lead to fragmentation (51), but 
optimizing codon depletion has also shown not to be able to improve the expressions (49). It 
is therefore not easy to confidently conclude that fragmentations occur due to codon bias.   
 
4.3 Purification 
Protein purification is a time elaborate procedure with no straightforward recipes to follow, 
as the different proteins will need to be treated uniquely. Main issues that are frequently met 
are protein degradation, protein insolubility, problems in preserving the protein structure, and 
protein aggregation. The plasmids used for this expression contain genes for 6x histidine 
residues, which allow purification of the recombinant protein by affinity chromatography. 
 After the expression and lysis of the LdAAP3 recombinant protein expressed in E. 
coli, we hoped that the target protein had been properly transcribed, folded, was free from the 
E. coli and that histidine residues attached were exposed on the surface of the molecule and 
not hidden in the conformational folding of the protein, to allow purification of the protein. 
After running SDS-PAGE and Western blots it was clear that we were not able to purify the 
lysated solution to obtain a solution with only our His-tagged recombinant protein. Several 
attempts were pursued with different conditions, but all attempts failed in yielding a 
completely purified protein in solution.  
 Our main problem was loosing the protein in early washing steps, rendering empty 
aliquots in the eluted solution, and unpurified aliquots in the washing steps where our 
recombinant proteins remain together with other proteins.  
 
4.3.1 Imidazole concentrations and denaturation conditions  
Different imidazole concentrations were tested to see when the protein would release their 
binding to the column or beads. Although the protein seemed to release their binding at 
different imidazole concentrations it was not possible to conclude that it was only because of 
the imidazole concentrations. Not only was there a difference when performing purifications 
with Dynabeads and columns, but also a difference in using different experimental 
conditions. 
If the protein has the histidine residue hidden in the conformational folding of the 
protein, it would hinder the binding to the IMAC resins. Attempts to denature the lysated 
solution during purifications were done in an attempt to improve the purification, without any 
further success (figure 20). Proteins were still lost during early washing steps, and eluted 
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solutions showed empty bands. The most successful elution was from protocol #12 (Figure 
25) using FT-NPI-250 buffer containing 250 mM imidazole.  
 
4.3.2 Binding to the IMAC 
The Dynabeads and the columns use Co2+ and Ni2+ based resins respectively, and it is said 
that Co2+ has a higher specificity for the His-tagged proteins compared to Ni2+ (68). The 
buffers used during purification varied in their concentrations of sodium phosphate, sodium 
chloride and imidazole. In addition, the amount of lysated sample varied rendering different 
concentrations of the proteins from the lysated E. coli. As mentioned earlier, doing a flow 
cytometric detection on these samples would have been interesting and might have given a 
more conclusive result when measuring the effects of the amount of our recombinant protein 
in the different aliquots from the purification step(49).   
It is not easy to point out why the purification was unsuccessful, and there are several 
possible explanations. Low access of the LdAAP3 His-tagged proteins to the immobilized 
Ni2+-chelated ligands could be one reason. This could be due to low affinities between the 
metal ion and our His-tagged LdAAP3 protein, or even low concentrations of the protein, 
which lead to reduced levels of adsorption to the column. Then again one must take into 
account the whole solution. If the E. coli solutions from the expression steps contains a lot of 
E. coli that has lost the recombinant plasmid, there will be a higher ratio of proteins produced 
that is not the LdAAP3 recombinant protein. This may lead to a crowded solution, making it 
difficult for the His-tagged proteins to bind to the IMAC resin. To long sonication may also 
lead to a more crowded solution, which seem to be the case during our experiments.  
The conformation and the surface accessibility of the His-tag of the recombinant 
protein are also important for the binding affinity to the metal ion resin. Interaction between 
the aromatic group of the ligand on the IMAC resins and the hydrophobic side chains of the 
His-tagged protein may cause steric hindrance due to hydrophobic pi stacking interactions, 
and may lead to lower binding affinity (69).  
Degradation and fragmentation is a common problem in the expression of the 
recombinant protein. Attempts in the purification process could be done to improve the 
extraction of the whole LdAAP3 recombinant protein by doing a two-step purification. This 
implies two tags cloned into the plasmid vector and could be placed at the Nter and the Cter. 
Only proteins with both tags will be purified (100). 
It is not common for bacteria cells to have histidine residues on their own proteins. 
Though this should result in low contamination of bacterial proteins during purification, 
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many of the host cell proteins bind, though weak, to the IMAC resin. These bindings can be 
due to host cell proteins with metal ion binding sites or the potential clustering on the surface 
of the protein that could mimic a His-tag. These proteins can be removed by adding a low 
concentration of imidazole that will compete for these binding sites (64).  
Although this was attempted, we still obtained a lot of other proteins. This can be 
explained by high concentrations of E. coli without our plasmid producing other proteins. 
The problem we experience during expression and purification may consequently be because 
of too high concentrations of E. coli growth without the plasmid. Attempts in lowering the 
growth and improving the selection of E. coli with plasmids seem to be important in future 
attempts.  
 
4.3.3 IMAC limitations:  
Although a popular method for protein purification, the IMAC system also has several 
limitations. All chelating agents that could strip the resin of the metal ions should be avoided, 
and was avoided during our experiments. Acidic pH could inhibit the binding between the 
resin and the target protein, which explains the method of elution using pH, which also failed 
to purify the target protein when tried out in this thesis (Figure 20). Metal ion transfer and 
leakage is some of the weaknesses when using IMAC. Having proteins with too strong 
affinity to the metal ion may remove the metal ions from the IMAC resin, resulting in protein 
loss due to proteins passing through the column with no binding. Zn2+ immobilized ions are 
claimed to be better than Cu2+ and Ni2+ because of their lower binding affinity to the host 
proteins (64). Attempts using column with Zn2+ could have been done. 
Cleavage of protein backbones and destruction of amino acid side chains can be 
caused by the IMAC complex. Amino acids like histidine found in the target protein can be 
vulnerable to metal-catalyzed oxidation reactions, which could lead to protein damage. Site-
specific cleavage can be initiated by metal ions sitting on the IMAC complex and cause 
fragmentation of the target protein (64).   
 
4.4 Quantification of protein 
Most quantification methods determine only the total protein content in a solution (101, 102). 
Because we were not able to purify the LdAAP3 recombinant protein, we did not have a 
purified solution that easily could be used for quantification. We therefore chose to run a 
SDS-PAGE, stain the gel with Coomassie blue. Thereafter we used ImageJ to analyze the 
	 86	
bands on the gel, to get an approximation of the quantity of our recombinant E. coli proteins. 
It allows us to compare band intensities(75). This method is semi-quantitative and several 
issues have to be considered when the analysis is performed.  
One of the main problems using this method relies on the different affinity of the 
proteins for Coomassie. It may not be appropriate to quantify the unknown E. coli protein 
bands based on an unstained ladder, since Coomassie may have different affinity for the two 
types of protein(103). Because of this a measured density of 1000 for a ladder band and 1000 
for an E. coli band does not mean the E. coli band contains the same amount protein as the 
ladder. A true concentration estimate is therefore not likely to be achieved. Further, when 
measuring band intensities saturation will eventually be achieved where differences will not 
be detected (75). ImageJ will then not be able to measure the difference between the two 
bands. This is why we made a serial dilution of the sample to see where this limit may be 
reached. If bands from the highest dilution are used for quantification, it may not give a good 
estimation. In addition to this, background also complicates the measurement further. In 
Figure 23, the peaks are not touching the baseline. This is due to background. 
Comparing densities of bands of different molecular weights may also be problematic 
and was done for our experiments. Using a known ladder with the same molecular weight as 
the unknown is preferable when using this method. This will allow more accurate density 
comparisons between the unknown and known bands.  
ImageJ simply measures the band intensities on the image. As long as the Coomassie 
binding has equal affinity to the various proteins, then ImageJ should be able to give a 
reliable measurement. But since we do not know the affinity to the different proteins, it is not 
easy to estimate how good this quantification can be. 
 
4.5 Raising anti-LdAAP3 polyclonal antibodies  
When raising antibodies sensitivity and selectivity of the antibody against the antigen 
is not guaranteed (104). Most antigen surfaces will be able to bind several possible 
antibodies. Any part of a surface that is accessible on an antigen can be a potential target of 
an antibody(105). Since polyclonal antibodies were produced it is likely that the antibodies 
will bind to several epitopes on the surface of the antigen. Because we wanted to raise anti-
LdAAP3 polyclonal antibodies for localization of AAP3 proteins in Leishmania parasites, 
producing the whole ORF LdAAP3 recombinant protein was not vital, though preferred. The 
fragments of LdAAP3 recombinant protein obtained from the expression and purification was 
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good enough to produce antibodies able to bind to the LdAAP3 protein in Leishmania 
amazonensis parasites.  
Sera obtained from rabbit immunization in Germany were not purified, which means 
that the sera contain several antibodies. Testing sensitivity and specificity requires positive 
and negative tests and subjects with and without infection. By purifying the antibodies over a 
protein A or G column, leaving us with only IgG, could have increased specificity and 
sensitivity further. A larger experiment should have been done to be able to conclude the 
specificity or sensitivity of the antibodies generated from infected subjects against LdAAP3 
antigens.  
 
4.6 Protein blotting 
Western blotting was performed to detect where the LdAAP3 recombinant proteins were 
localized throughout the expression and purification. For detection of His-tagged proteins, 
alkaline phosphatase conjugated His-tag antibodies were used. A weakness when using this 
method is that it only detects His-tagged proteins, and not the LdAAP3 proteins specifically.  
 
4.6.1 Detecting the His-Tagged LdAAP3 recombinant proteins 
His-tag detection allowed us to choose the bands we knew had His-tag on, making us more 
confident about the choice of protein to cut out from the gel for immunization of the rabbit. 
The Western blots using AP conjugated antibodies for His-tag detection generally showed us 
strong bands of the repeated fragments of the LdAAP3 recombinant protein occurring at a 
size of about 32 kDa and 26 kDa. It also showed weak bands at a size of 56 kDa (figure 24). 
This may indicate that the production of the whole ORF LdAAP3 recombinant protein is 
modest, and that the problem may be during the expression of the recombinant protein and 
not necessarily due to fragmentations of the whole ORF LdAAP3. Looking at Figure 20, 
showing the results from protocol #11, may further support this. Protease inhibitors were 
added during this protocol, but did not improve the yield of the whole ORF LdAAP3 
recombinant protein. Improving the expression protocol by lowering temperature, decreasing 
plasmid number, and adding co-expression of chaperones may have aided the expression.   
 
4.6.2 Blotting LdAAP3 recombinant protein on nitrocellulose membrane  
Using Ni-NTA buffers and column gave us a more successful purification. Although not 
shown on the Western blot (Figure 25) we could see bands at around 56 kDa on the SDS-
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PAGE, on FT-NPI-250 aliquots. The band at the size of 56 kDa is repeatedly seen when 
using sera from infected subjects (figure 25, 26, 29 and 30).  This aliquot from FT-NPI-250 
had few other bands on the gel and also had a His-tag verification of the protein at a size of 
about 26 kDa on the Western blot. When choosing aliquots to be used as antigen to be blotted 
on the nitrocellulose paper, we chose to mix NPI-20 and NPI-250 together. This was done 
because both aliquots showed strong bands in different places on the Western blot, giving us 
two arias  (26 kDa and 38 kDa) where we could expect antibody binding to the 
epitope/antigen, and be able to use this as a marker when comparing with infected sera. 
Mixing these two aliquots and not using the most purified aliquot alone could increase the 
unspecific binding on the nitrocellulose membrane due to the increased sites of antigen that 
different antibodies from sera could bind to (76).  
 
4.6.3 Testing sera from Leishmania infected and non-infected individuals   
Optimal detection methods that are suitable for field applications are lacking for 
leishmaniasis. Lack of specialized skills, laboratory equipment and easy detection methods 
limit the ease of detection in endemic areas (106). Antibodies detected by Western blotting 
have been done for L.donovani, where samples of whole parasite were blotted onto a 
nitrocellulose membrane and tested with serum from patients (14, 15). The experiments we 
performed using sera from infected individuals were meant to explore whether infected 
subjects could be detected by using blotted nitrocellulose papers containing the LdAAP3 
recombinant antigen as detection marker.  
Sera from mice infected with L. amazonensis, and sera from human infected with L. 
infantum chagasi were tested for binding against the LdAAP3 recombinant protein produced.  
 Negative and healthy controls of mice sera did not reveal any bands on the blotted 
nitrocellulose strips, indicating that the bands we got from the infected sera may come from 
antibodies generated from infection (Figure 27). Bands showing at the same sizes as the 
bands from earlier Western blots with His-tag detection may indicate that the antibodies 
generated in infected subject are selective for antigen from LdAAP3 recombinant protein.  
Not only did the antibodies from infected sera bind at the same position as the His-
tagged protein bands from the Western blot (38 and 28 kDa) (Figure 25), but it also bind to 
several sites on the LdAAP3 recombinant blotted nitrocellulose membrane, at sizes around 
56, 49, 38, 28 and 12 kDa (Figure 26 and 27). Bands at around 56 kDa that are shown on 
several SDS-PAGE ( Figure 18-20) and not on Western blots seem to occur on the strips 
blotted with LdAAP3 recombinant protein solution incubated with infected sera. Because this 
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binding is not detected by His-tag affinity during Western Blots but rather detected during 
antibody-epitope binding, it can be that the His-tag residues are cut off. This can also explain 
the challenges we met when purifying the recombinant solution using Nter His-tag affinity. 
Adding His-tag on the Cter protein could have been tested. 
The LdAAP3 nitrocellulose strips incubated with human sera with L. infantum 
infection showed a band at about 38 kDa. The person used as healthy human control was 
chosen because he had never had any symptoms indicating infection with Leishmania. This 
does not have to mean that he was not infected, since the disease could be asymptomatic. A 
problem with the protocol for human sera was the use of 3 three layers of antibodies (human, 
goat anti human and anti goat IRDye 680), which could lead to more unspecific binding and 
produce irregular results. This may also be due to the binding to E. coli proteins that may be 
on the blotted nitrocellulose membrane, as the recombinant proteins were expressed in E. 
coli. Several control tests should have been conducted to be able to conclude further. 
 From the experiments we conducted we could see the same bands at the same 
sizes appeared repeatedly. Sera from L. amazonensis infected mice, seem to bind to the L. 
donovani AAP3 recombinant protein. This could indicate affinity between the antibody from 
infected sera and the LdAAP3 recombinant antigen, which may further support the fact that 
the AAP3 protein is conserved between the different species of Leishmania. However, 
similar epitopes could generate affinities for the same antibody and generate cross-reactions 
that can occur with distantly related organisms (107, 108). Because of this, diagnostic 
accuracy may decrease and be less reliable. Cross reaction with Trypanosoma cruzi has been 
confirmed and is one of the setbacks when using detection by antibodies, which have led to 
significant false positive reactions, which further complicates the analysis (109). This is the 
fact for the immnochromatographic strip test using the rK39 recombinant antigen, which 
gave positive results in patients with malaria, tuberculosis or typhoid fever (15, 16). This 
underlines the importance of generating antibodies specific for Leishmania parasite. Several 
tests could therefore have been performed, to analyze the antibody for cross reactivity. 
To improve the comparison between infected and uninfected sera it would have been 
better to use the same subjects before and after infection. This is possible for animal subjects. 
Human subjects should have been obtained from non-endemic areas.  
 It must be noted that the sera is not purified. This could increase the background and 
give false positive reactions due to the nonspecific antibody binding. Another weakness was 
the usage of BSA or dry milk, which both contained bovine IgG. A lot of secondary 
antibodies, such as anti-goat Ig, can react strongly with bovine IgG. The secondary antibody 
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used on human sera was anti goat IRDye 680 (Odyssey-Licor). This could explain the 
increased background (110).  
 
4.6.4 Testing anti-LdAAP3 polyclonal antibodies against E. coli produced LdAAP3 proteins 
The affinity of the polyclonal antibodies produced in rabbit injected with our recombinant 
LdAAP3 protein was tested against the recombinant LdAAP3 protein blotted on a 
nitrocellulose membrane. Again we could detect bands with a similar kDa sizes as mentioned 
earlier, showing bands at the sizes around 38 and 28 kDa, further supporting our other results 
indicating that these bindings are not random and a cause to unspecific bindings, but on the 
contrary indicate binding between the recombinant protein and antibodies with affinity to its 
epitope.  
Several bands were detected on the Western blot in figure 29, but clear bands could 
be detected at 56 kDa and 26 kDa. This could again indicate the successful production of the 
whole LdAAP3 recombinant protein detected by antibody binding to epitope, which may 
indicate that the His-tag is hidden in the conformational folding of the LdAAP3 protein.  
 Although the rabbits were immunized with either 32 kDa or 26 kDa size purified 
recombinant LdAAP3 protein, the antibodies produced seem to detect bands at several sizes. 
This can be explained by the generation of epitopes and antibody affinity. Antibodies 
produced from immunized rabbits may recognize different epitopes on the blotted target 
protein. Epitopes in the beginning of the 56 kDa protein may be the same as the epitopes 
from the 26 kDa protein. The antibodies produced from injection of the 26 kDa size proteins 
may therefore be able to detect bands in other sizes.  
A few bands on the pre-immune strips also occurred (Figure 31). Because the bands 
do not occur at the same size, it most likely cannot be due to the bacterial production of its 
own alkaline phosphatase proteins which might react with the AP conjugated His-tag 
antibody used for detection. A possible explanation could be antibody production in the 
rabbit from earlier exposure to E. coli, which now recognizes some epitopes on the LdAAP3 
membrane blotted nitrocellulose membrane. This can be explained because the LdAAP3 
recombinant solution blotted on the nitrocellulose membrane was produced in E. coli. 
Proteins from the E. coli would therefore most likely be on the membrane.  
 
4.6.5 Testing SLA and recombinant LdAAP3 against anti-LdAAP3 antibody using ELISA  
The LdAAP3 recombinant protein and soluble lysated antigens (SLA) from Leishmania 
amazonensis were tested against the polyclonal antibodies produced. The polyclonal 
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antibodies produced from the LdAAP3 recombinant protein will consist of a mixture of 
different antibodies produced by many different B cells. The same results occurred showing 
clear differences in titer levels of pre-immune and immune rabbit, indicating the successful 
production of polyclonal antibodies against the recombinant protein.  
 Titers of SLA showed increased titers of animal 71, 72 and 74. Indicating that there is 
affinity between sera from immunized recombinant protein and antigens produced from 
lysated Leishmania. Where these bindings occur is hard to determine. We can therefore not 
determine whether these interactions are between the AAP3 protein in Leishmania or simply 
interactions with other antigens with similar epitopes. This must be further interpreted in 
different analysis like using confocal microscopy.  
 



















































The antibodies that we have produced might also be possible to use for localization of 
the parasite in the body, both during the infection process and after establishment of the 
infection. This may allow treatment of specific organs or tissues. Again an obstacle would be 





















































































































































































































































































































































A Kits used during the project 
Kit name  Supplier  Catalog/Lot 
number 
QIAquick PCR Purification 
Kit 
Qiagen 










USA, 5791 Van Allen Way, 
Carlsbad, CA 92008 
- 
Dynabeads His-Tag Isolation 
& Pulldown  
Life Technologies. 
Norway, Oslo 
Ref: 10103D (2 ml) 
Lot: 167525800 
HisTrapTM HP, 5 x 1ml  GE Healthcare Life 
Sciences.  
SE-751 84 Uppsala, Sweden 
17-5247-01 
Lot: 10236714 
NuPAGE 4-12% Bis-Tris Gel 
(1.0mmX10well)  
Life Technologies. 
USA, 5791 Van Allen Way, 
Carlsbad, CA 92008 
Ref: NP0321BOX 
LOT: 15090471 
NuPAGE 4-12% Bis-Tris 
Gel¨(1.5mmX15well) 
Life Technologies. 
USA, 5791 Van Allen Way, 




Immunodetection System (for 
detection of Mouse Primary 
Antibodies)  
Invitrogen. 
USA, Carlsbad, CA 92008, 
760 603 7200  
Cat: WB7103 
Lot: 1089126 
Champion pET151 Directional 
TOPO Expression Kit 
  
Invitrogen 
Life technologies.  
USA, 5791 Van Allen Way, 
Carlsbad, CA 92008 
K151-01 
PureLink Quick Plasmid 
Miniprep Kit 
Invitrogen  
Life technologies  
USA, 5791 Van Allen Way, 
Carlsbad, CA 92008 
 
Cat: K2100-10 







B Instruments  
 
Photometer 
Eppendorf BioPhotometer, with 8,5mm cuvette (Hamburg, Germany).  
 
Sonicator 
Misonix, Sonicator 3000 Ultrasonic Liquid processor (Newton, CT, USA)  
 
Centrifuge 
1. Centrifuge 5810 R (Ependorf, Hamburg, Germany)  
2. Centrifuge 5430 R (Eppendorf, Hamburg, Germany)  
3. Centrifuge 5415 D (Eppendorf, Hamburg, Germany)  
4. Ultracentrifuge, Beckman, USA  
5. Sorvall RC 5C Plus, Dupont, (Wilmington, Delaware, USA), using a Sorvall SS-34 rotor.  
 
Shaker 
1. HT INFORS minitron  (Infors AG, Bottmingen/Basel, Switzerland).  




1. Stuart, Rotator SB3 (Stone, United Kingdom).  
2. The Belly Dancer, Stovall (Greensboro, NC, USA).  
 
PowerBank 
1. PowerNPac 300, Bio-Rad (USA).  
2. PowerPac Basic, Bio-Rad (USA).  
 
Thermomixer 
Eppendorf Thermomixer Comfort (Eppendorf, Hamburg, Germany)  
 
Incubator 
1. Termaks, Type: B8420, Labolytic AS, (Bergen, Norway).  




Labinco vortex mixer (Breda, The Netherlands).  
 
Chamber for Western blot 
X Cell II, Blot Module, InVitrogen, Life Technologies (Carlsbad, CA, USA)  
 
Scanner 
LI-COR Inc, Odyssey, CLx Infrared Imaging System (Lincoln, NE, USA).  
 
C Computer software 
Word 
Word 2011 (Microsoft Corporation, Santa Rosa, California, USA) was used to write and edit 
the thesis.  
 
Excel 
Excel 2011 (Microsoft Corporation, Santa Rosa, CA, USA) was used to calculate results 
from ImageJ.  
 
ImageJ: 



















D Vectors:  
 
 























































































E Contents of solutions used  
Buffers for lysis 
Solution  Ingredients  
Lysis buffer 1 
Adjust to 50 mL solution with 
Milli-Q water 
(pH 8.0) 
20 mM Sodium Phosphate pH 8.0 (1 mL, from 
1M stock) 
500 mM NaCl (5 mL, from 5M stock) 
5 mM imidazole (10 𝜇L, from 5M stock) 
1 mM PMSF (add only at time of use) 
0.2 mg/ml lysozyme (add only at time of use) 
Lysis buffer 2 
Adjust to 50 mL solution with 
Milli-Q water 
(pH 8.0) 
Filter with 0.2 𝝁m.  
5 mL of 1M NaH2HPO4(1M) 
500 𝜇L Tris (100%) 
40 mL UREA (10M) 
 
1M Sodium phosphate buffer  
(pH 8) 
Filter with 0.2 𝝁m. 
6,8 mL of 1M NaH2HPO4 (12g to 100 mL water) 
93,2 mL of 1M Na2HPO4(14,2g to 100 mL water) 
Solubilization buffer 
Solution  Ingredients  
Solubilization buffer  
Adjust to 40 mL solution with 
Milli-Q water 
(pH 8.0) 
20mM Sodium Phosphate pH 8 (0,8 mL, from 1M 
stock) 
300mM NaCl (2,4 mL, from 5M stock) 




















Buffers for Dynabeads purification   
Solution  Ingredients  
1Dynabeads – binding buffer 
Adjust to 10 mL solution with 
Milli-Q water 
100 mM Sodium Phosphate pH 8 (1 mL, from 1M 
stock) 
600 mM NaCl (1,2 mL, from 5M stock) 
5 mM imidazole (10 𝜇L, from 5M stock) 
0,2% Tween-20 (20 𝜇L) ) 
1Dynabeads–washing buffer1 
Adjust to 10 mL solution with 
Milli-Q water 
(pH 8.0) 
100 mM Sodium Phosphate pH 8 (1 mL, from 1M 
stock) 
600 mM NaCl (1,2 mL, from 5M stock) 
5 mM imidazole (10 𝜇L, from 5M stock) 
1Dynabeads–washing buffer2 
Adjust to 10 mL solution with 
Milli-Q water 
(pH 8.0) 
100 mM Sodium Phosphate pH 8 (1 mL, from 1M 
stock) 
600 mM NaCl (1,2 mL, from 5M stock) 
30mM imidazole (60 𝜇L, from 5M stock) 
1Dynabeads–washing buffer3 
Adjust to 10 mL solution with 
Milli-Q water 
(pH 8.0) 
100mM Sodium Phosphate pH 8 (1 mL, from 1M 
stock) 
600mM NaCl (1,2 mL, from 5M stock) 
75mM imidazole (150 𝜇L, from 5M stock) 
1Dynabeads – elution buffer 




50mM Sodium Phosphate pH 8 (1 mL, from 1M 
stock.  
300mM NaCl (1,2 mL, from 5M stock) 
0,10% Tween-20 (10 𝜇L.) 
300mM imidazole (600 𝜇L, from 5M stock) 
2Dynabeads – 1Xbinding/wash 
buffer Adjust to 10 mL solution 
with Milli-Q water 
50mM Sodium Phosphate pH 8 (0,5 mL, from 1M 
stock) 
300mM NaCl (0,6mL, from 5M stock) 
0,01% Tween-20 (1𝜇L)  
2Dynabeads–elution buffer 




50mM Sodium Phosphate pH 8 (0,5 mL, from 1M 
stock) 
300mM NaCl (0,6mL, from 5M stock) 
0,01% Tween-20 (1𝜇L) 
300mM imidazole (600𝜇L, from 5M stock) 
	 107	
HisTrap HP purification  
Solution  Ingredients  
1HisTrap HP – binding buffer  
Adjust to 50 mL solution with 
Milli-Q water 
(pH 8.0) 
20mM Sodium Phosphate (1000 𝜇L, from 1M 
stock) 
500mM NaCl (5000 𝜇L, from 5M stock) 
5mM imidazole (50 𝜇L, from 5M stock) 
1HisTrap HP – washing buffer 1 
Adjust to 50 mL solution with 
Milli-Q water 
(pH 8.0) 
20mM Sodium Phosphate (1000 𝜇L, from 1M 
stock) 
500mM NaCl (5000 𝜇L, from 5M stock) 
20mM imidazole (200 𝜇L, from 5M stock 
1HisTrap HP – washing buffer 2 
Adjust to 50 mL solution with 
Milli-Q water 
(pH 8.0) 
20mM Sodium Phosphate (1000 𝜇L, from 1M 
stock) 
500mM NaCl (5000 𝜇L, from 5M stock) 
75mM imidazole (750 𝜇L, from 5M stock) 
1HisTrap HP – washing buffer 3 
Adjust to 50 mL solution with 
Milli-Q water 
(pH 8.0) 
20mM Sodium Phosphate (1000 𝜇L, from 1M 
stock) 
500mM NaCl (5000 𝜇L, from 5M stock) 
200mM imidazole (2000 𝜇L, from 5M stock) 
1HisTrap HP – elution buffer  
Adjust to 50 mL solution with 
Milli-Q water 
(pH 8.0) 
20mM Sodium Phosphate (1000 𝜇L, from 1M 
stock) 
500mM NaCl (5000 𝜇L, from 5M stock) 
500mM imidazole (5000 𝜇L, from 5M stock) 
2HisTrap HP – lysis buffer  




1M NaH2HPO4 (5 mL) 
Tris (500 𝜇L)                            Stock lysis buffer 
10M Urea (40 mL)      
Took out 15ml of stock lysis buffer and added: 
1mM EDTA (30 𝜇L from 0,5M stock) 
1mM PMSF (150 𝜇L from 100mM stock) 
10 𝜇M TLCK (15 𝜇L from 10mM stock) 
2 𝜇g/mL Leupeptin (30 𝜇L from 1mg/ml stock) 
1 𝜇g/mL Aprotinin (15 𝜇L from 1mg/ml stock) 
0,2 mg/mL Lysozyme (30 𝜇L from 100mg/ml 
stock) 
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2HisTrap HP – washing buffer 1 
Adjust to 50 mL solution with 
Milli-Q water 
(pH 6.3) 
1M NaH2HPO4 (5 mL) 
Tris (500 𝜇L)                             
10M Urea (40 mL)      
 
2HisTrap HP – washing buffer 2 
Adjust to 50 mL solution with 
Milli-Q water 
(pH 5.3) 
1M NaH2HPO4 (5 mL) 
Tris (500 𝜇L) 
10M Urea (40 mL)     
 
2HisTrap HP – elution buffer  
Adjust to 50 mL solution with 
Milli-Q water 
(pH 4.0) 
1M NaH2HPO4 (5 mL) 
Tris (500 𝜇L) 
























Buffers for Ni-NTA Superflow 
Solution Ingredients 
NPI-10 (Binding/lysis buffer for native 
conditions) 
Adjust to 1L solution with Milli-Q water 
(pH 8.0) 
Filter before use with 0,2𝛍𝐦 
50mM NaH2HPO4 (6.9g, MW: 
137.99g/mol) 
300mM NaCl (17.54g, MW: 
58.44g/mol) 
5mM imidazole (0,34g, MW 68,08 
g/mol) 
NPI-20 (Wash buffer for native 
conditions) 
Adjust to 1L solution with Milli-Q water 
(pH 8.0) 
Filter before use with 0,2𝛍𝐦 
50mM NaH2HPO4 (6.9g, MW: 
137.99g/mol) 
300mM NaCl (17.54g, MW: 
58.44g/mol) 
20mM imidazole (01,36g, MW 
68,08 g/mol) 
NPI-250 (Elution buffer for native 
conditions) 
Adjust to 1L solution with Milli-Q water 
(pH 8.0) 
Filter before use with 0,2𝛍𝐦 
50mM NaH2HPO4 (6.9g, MW: 
137.99g/mol) 
300mM NaCl (17.54g, MW: 
58.44g/mol) 
250mM imidazole (17.0g, MW 
68,08 g/mol) 
Buffer E (denaturating elution buffer)  
Adjust to 1L solution with Milli-Q water 
(pH 4.5) 
Filter before use with 0,2𝛍𝐦 
8M urea (480.5g, MW: 
60.06g/mol) 
100mM NaH2HPO4 (13.80g, MW: 
137.99g/mol) 
100mM Tris-base (12.10g, MW: 












Buffers for Western blot 
Solution  Ingredients  
TBS 1x 
Adjust to 1L solution with Milli-Q 
water 
(pH 7.5) 
Filter with 0,45𝛍𝐦 
50mM Tris-Cl (6,05g) 
150mM NaCl (8,7g) 
Solution is stable at 4℃ for 3 months  
 
TBST 0,1% Tween20 (100 𝜇L, from 100% stock) 
100mL TBS solution  
Transfer buffer  
Adjust to 1L solution with Milli-Q 
water 





50ml TBS solution  
5% BSA (2,5g)  
Dilution buffer  10ml TBST 
5% BSA (0,5g)  
Alkaline phosohatase buffer  
(pH 9.5) 
Adjust to 50mL solution with 
Milli-Q water 
Filter with 0,2𝛍𝐦 
100mM diethanolamine/TRIS (5000𝝁L, from 1M 
stock) 
100mM NaCl(1000𝝁L, from 5M stock) 
5mM MgCl2 (250𝝁L, from 1M stock) 
	
Buffers for Odyssey  
Solution  Ingredients  
PBS 1x 
Adjust to 1L with Milli-Q water 
Adjust pH to 7,2 -7,4 with 
NaOH/HCl. Auoclavate 
137mM (8g) 
2.7mM KCl (200mg) 
10mM Na2PO4O (1,44g) 
2mM KH2PO4O (240mg) 
PBST 0,1% Tween20 (100 𝜇L, from 100% stock) 
100ml PBS solution  
Blocking buffer 
Adjust with Milli-Q water to a 
total amount of 500mL  
Nonfat-Dried milk (0.1%) 
To 0.2x of PBS 
Added 0.2% Tween20 
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